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SUMMARY
Dientamoeba fragilis is a protozoan parasite of the human bowel,
commonly reported throughout the world in association with gas-
trointestinal symptoms. Despite its initial discovery over 100 years
ago, arguably, we know less about this peculiar organism than any
other pathogenic or potentially pathogenic protozoan that infects
humans. The details of its life cycle and mode of transmission are
not completely known, and its potential as a human pathogen is
debated within the scientific community. Recently, several major
advances have been made with respect to this organism’s life cycle
and molecular biology. While many questions remain unan-
swered, these and other recent advances have given rise to some
intriguing new leads, which will pave the way for future research.
This review encompasses a large body of knowledge generated on
various aspects of D. fragilis over the last century, together with an
update on the most recent developments. This includes an update
on the latest diagnostic techniques and treatments, the clinical
aspects of dientamoebiasis, the development of an animal model,
the description of a D. fragilis cyst stage, and the sequencing of the
first D. fragilis transcriptome.
INTRODUCTION
Dientamoeba fragilis is a single-celled protozoan parasitelargely ignored by medicine as a cause of human gastrointes-
tinal (GI) disease and is often described as a “neglected parasite.”
Despite regular, continuous reports emerging over the last 100
years that describe an association between D. fragilis and human
GI disorders, including diarrhea, it is still often ignored as a patho-
gen, and routine testing may not be routinely conducted by diag-
nostic laboratories. Indeed, knowledge on the basic biology of this
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species is scant at best. As a result, we remain ignorant of this
parasite’s host distribution, its life cycle, and many other aspects of
its biology. However, recent developments have been made in the
field of D. fragilis research, which are changing this profile. The
design and development of new, modern diagnostic tests for D.
fragilis have been associated with a major increase in the rate of
detection of this parasite in cases of GI disease. This in turn has
resulted in a reassessment of historical knowledge on D. fragilis,
particularly its potential role as a human pathogen. This review
focuses on D. fragilis as a cause of human disease and on its diag-
nosis and treatment and provides an update on our current un-
derstanding of its biology and life cycle.
HISTORICAL ASPECTS
The distinguished English protozoologist Charles Wenyon is
credited with the discovery of D. fragilis in 1909 after examining
his own parasitological stool preparations. However, it was not
until 1918 that Margaret Jepps and Clifford Dobell described the
parasite in the scientific literature (1). As this protozoan was very
different from the amoebae that were known to occur in the hu-
man bowel at that time, they reported that “it differs in some
respects so conspicuously from the others that it appears to us
necessary to place it not only in a new species, but even in a new
genus” (1).
Jepps and Dobell (1) described D. fragilis as a binucleate
amoeba between 8 and 10 m in diameter. Due to the fragile
nature of the organism, in the form of rapid morphological de-
generation once passed outside the human body, the name D.
fragilis was given to this new parasite. While D. fragilis was con-
sidered to be an amoeboid organism, it was not long until Dobell
challenged the validity of this nomenclature. Through many ex-
periments, he concluded that the nuclear apparatus of D. fragilis
was flagellate-like and that its method of nuclear division was not
characteristic of an amoeba but was more like that of a flagellate
(2). He postulated that D. fragilis was a flagellate and undertook
several experiments to induce the organism to express a flagellum,
all of which were unsuccessful. Despite these initial findings, Do-
bell documented the similarities between D. fragilis and the amoe-
boflagellate Histomonas meleagridis (a pathogen of poultry and
birds) (3). Dobell subsequently concluded that Dientamoeba was a
flagellate, which somewhere along its evolutionary development
had permanently lost its flagella. Dobell’s hypothesis that Dienta-
moeba was indeed an “unflagellated” flagellate was shown to be
correct, as later researchers verified the close relationship between
D. fragilis and the other flagellates, especially H. meleagridis (4–7).
His assumptions at the time were not entirely correct, as it seems
that D. fragilis has not permanently lost its flagella, just the ability
to express them externally, as flagellum-like structures have been
visualized via transmission electron microscopy (8).
Both Dobell and Jepps initially thought that D. fragilis was
nonpathogenic in spite of noting six of seven patients who suf-
fered from dysentery or chronic diarrhea and finding only one
sample from asymptomatic patients after screening numerous
healthy persons (1). It was not long until other researchers started
to question the pathogenicity of D. fragilis. In 1919, a year after D.
fragilis was first described in the literature, Kofoid et al. reported
D. fragilis in military officers from the United States who suffered
from bowel complaints (9). The following year, another study
found D. fragilis in three symptomatic children in the Philippines
(10), and later, D. fragilis was implicated as a cause of diarrhea in
an adult male from England (11). Thus, in the space of 4 years
following the discovery of D. fragilis, controversy surrounding its
pathogenicity arose and persists to this day.
TAXONOMY
Jepps and Dobell were the first to not only describe D. fragilis in
the literature but also to assign it a taxonomic position (1). In
1918, three Entamoeba species were known to occur in the human
bowel: the nonpathogenic species Entamoeba coli and Entamoeba
nana (now known as Endolimax nana) and the pathogenic species
Entamoeba histolytica. While this new protozoan was placed in the
family Entamoebidae, Jepps and Dobell (1) argued that as it had a
binucleated form and no cyst stage, it not only was a new species
but also warranted the formation of a new genus. They demon-
strated that once outside the human body, this organism became
“fragile” and degenerated rapidly. Subsequently, the name Dien-
tamoeba fragilis was given and remains in use today.
Dobell would continue his research on this organism for many
years to come. Using only microscopy and culture techniques,
Dobell came to recognize the close structural similarities between
D. fragilis and H. meleagridis, in particular the dividing stages of
these two organisms (2). Notably, Dobell observed that the nuclei,
chromosomes, and centrodesmus were similar between the two
organisms. He also recognized the differences between other
amoebae and D. fragilis, such as the predominately binucleate
form of trophozoites; the distinct nuclear structure; the extranu-
clear spindle, which is present in dividing organisms; the apparent
absence of cysts from the life cycle; and similarities with other
flagellates. Having collected this information, Dobell postulated
that D. fragilis was a flagellate that had somehow lost its flagella
permanently. Wenrich also documented the similarities between
D. fragilis and H. meleagridis and found that both organisms
shared many flagellate characteristics (12). On the basis of the
above-mentioned scientific data and because D. fragilis was signif-
icantly different from other amoebae, in 1953, D. fragilis was re-
classified and placed into the family Dientamoebidae along with
Histomonas (13).
The advent of electron microscopy enabled studies that would
substantiate the hypothesis that D. fragilis was indeed closely re-
lated to the flagellates described by Dobell and Wenrich. Bird et al.
(14) reported a series of electron micrographs that illustrated the
fine structure of uni- and binucleate trophozoites of D. fragilis.
The demonstration of a persistent internuclear spindle of micro-
tubules in the binucleate stage supported Dobell’s assumptions.
Also, the well-developed parabasal filament in both uninucleated
and binucleated trophozoites of D. fragilis substantiated its close
affinity with H. meleagridis.
Dwyer used gel diffusion and quantitative fluorescent-anti-
body methods to analyze the antigenic relationships among Dien-
tamoeba, Histomonas, Trichomonas, and Entamoeba (15–17).
These results demonstrated that Dientamoeba, Histomonas, and
Trichomonas shared many closely related antigens with each other
and far fewer with Entamoeba. Two years later, immunoelectro-
phoresis techniques were employed to analyze the antigenic rela-
tionships among these same species, and the close antigenic rela-
tionship among Dientamoeba, Histomonas, and Trichomonas was
confirmed once more (18). It was also evident that Dientamoeba
shared an antigenic basis with Histomonas while being distinct
antigenically from Entamoeba histolytica and Entamoeba invadens
(18).
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554 cmr.asm.org July 2016 Volume 29 Number 3Clinical Microbiology Reviews
 on M








In 1974, by using electron microscopy, a further taxonomic
revision of Dientamoeba occurred. Several similarities between
Dientamoeba and Histomonas were noted, especially with regard
to the parabasal apparatus. It was also evident from the electron
micrographs that there were many structural differences between
Dientamoeba and Entamoeba. On the basis of these findings, D.
fragilis was placed in the order Trichomonadida and the family
Monocercomonadidae, subfamily Dientamoebidae (19). In 1980,
Levine et al. reclassified Dientamoeba in the order Trichomona-
dida (20).
Molecular techniques were first used in 1996 to determine the
taxonomic position of Dientamoeba. Molecular phylogenies were
constructed based on the complete small-subunit (SSU) rRNA
sequences of D. fragilis (21). The D. fragilis SSU rRNA gene was
shown to have a GC content that was low compared to those of
other trichomonads and to contain 100 extra nucleotides. All
phylogenic constructions showed that D. fragilis was closely re-
lated to trichomonads (21). Additional molecular studies using
the SSU rRNA gene loci were unable to resolve the phylogenetic
position of D. fragilis in comparison to other parabasalids (22).
When analysis of the SSU rRNA gene of H. meleagridis was under-
taken (6), the sequence data also showed a reduced GC content
and an increased sequence length, similar to what was observed
for D. fragilis.
Phylogenetic studies confirmed a close relationship between D.
fragilis and H. meleagridis and indicated that both organisms share
a recent common ancestor, which probably exhibited a more
complex cytoskeletal structure. This idea was supported by the
phylogenetic studies of Gerbod et al. (6), who suggested that the
morphology of both species probably arose through a secondary
loss or reduction of some cytoskeletal structures. Recent phyloge-
netic studies of the Parabasalia using protein sequences have also
confirmed the close relationship of these two organisms (as sister
groups) (23, 24) (Fig. 1).
A major critical taxonomic revision of the Parabasalia (25) is
yet to be completely acknowledged. A recent revised classification
scheme for D. fragilis (Table 1) is based on the above-mentioned
reports and indicates that D. fragilis belongs to the Dientamoebi-
dae family of the newly revised class Tritrichomonadidae and the
order Tritrichomonadida of the Parabasalia (25), which contains
the previously recognized families Tritrichomonadidae, Monoc-
ercomonadidae, and Simplicimonadidae. The new Dientamoebi-
dae family contains four genera, Dientamoeba, Histomonas, Para-
histomonas, and Protrichomonas, based on criteria such as the
number of nuclei, presence of flagella, and absence of a costa.
Recent electron microscopy studies of cultured trophozoites (7)
and cysts produced by rodents (8) have enhanced our knowledge
in this area, particularly in the recognition of flagellum-like struc-
tures in the cyst. Cysts possess a well-developed cyst wall that
encloses an amoeboid-shaped cell, and the cyst diameter is typi-
cally within the range of 4 to 6 m. The cysts contain one or two
nuclei, and the nuclear membrane is often not visible, suggesting
that karyogamy may be occurring during cyst development. Hy-
drogenosomes and a basal body structure are present in D. fragilis
cysts, which also possess an axostyle, flagellar axonemes, pelta, and
a costa (8). In contrast, the pelta and flagella are absent in tropho-
zoites (7). The presence of a costa is not associated with an undu-
lating membrane in either the cyst or the trophozoite. The tropho-
zoites move by the crawling action associated with cytoplasmic
streaming of pseudopodia.
GENETIC DIVERSITY
Based on current literature, there are two major D. fragilis geno-
types, genotype 1 and genotype 2 (also known as the Bi/PA strain),
with genotype 1 being the most common subtype (26–28). Orig-
inally, the distinction between these genotypes was made based on
FIG 1 Molecular phylogenetic analysis of RNA polymerase II largest-subunit protein sequences from various trichomonads, including D. fragilis. The GenBank
accession number for each sequence is shown in parentheses. The evolutionary history was inferred by using the maximum likelihood method based on the Jones,
Taylor, Thornton (JTT) matrix-based model (199). The percentage of trees in which the associated taxon cluster together is shown next to the branches.
Evolutionary analyses were conducted with MEGA6 (200). The robustness of the tree was assessed by using the bootstrap method with 1,000 replicates.
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differences between their 18S rRNA sequences (29–31), although
these differences are minor (2 to 4%) (30, 32). In a recent study
(32), the actin and elongation factor 1 genes for both D. fragilis
genotypes were compared, and it was found that the differences in
these genes were also very minimal (3%), suggesting that the
two genotypes diverged recently. As such, genetic diversity ap-
pears to be limited in D. fragilis, although very few genes and
isolates have been examined so far.
Several reports indicate that diversity may exist (or does exist)
in genes other than those studied previously. Barratt et al. (33)
describe phenotypic differences between the in vitro growth char-
acteristics of different clinical D. fragilis isolates and suggested that
they might have a genetic basis. All D. fragilis isolates included in
the study by Barratt et al. (33) were confirmed to be genotype 1
isolates, so any potential genetic diversity must exist in other
genes. Windsor et al. (34) identified the multicopy internal tran-
scribed spacer (ITS) genes as a source of genetic diversity within
individual D. fragilis isolates, which is unusual among protozoa.
This observation eventually led to the development of a C-profil-
ing technique, which could be used to distinguish between isolates
(35, 36). In another report, Hussein et al. (37) detected diversity in
the 18S RNA genes of isolates derived from patients with irritable
bowel syndrome (IBS) by using PCR with high-resolution melt
curve analysis. While those authors noted differences between iso-
lates, they did not include samples from asymptomatic individuals
(37). As such, it is unknown whether this technique might be
useful for differentiating between virulent and avirulent strains of
D. fragilis.
Dientamoeba fragilis strains that infect animals may also be
distinct from human strains. According to Caccio et al. (38), two
populations of D. fragilis were identified in a population of swine
based on 8 single nucleotide polymorphisms (SNPs) observed fol-
lowing sequencing of PCR products amplified from the SSU rRNA
gene. Given this small number of differences, however, these par-
asites were still considered to belong to the D. fragilis genotype 1
SSU subtype. Other investigators also demonstrated that there is
very little diversity in the SSU rRNA genes of D. fragilis isolates
(32). Subsequently, the search for diversity should include exam-
ination of other genes. This is in line with current theories of
molecular evolution that link times of evolutionary divergence
with the number of mutations found in coding and noncoding
regions of the genome.
Many enteric protozoa exhibit extensive genetic diversity in
genes other than the rRNA genes in the absence of morphological
variation. Indeed, protozoa that were originally thought to be one
species have subsequently been found to comprise two or more
new species. Entamoeba histolytica and Entamoeba dispar repre-
sent one such example. These organisms are morphologically
identical and exhibit remarkable similarity at their SSU rRNA
gene loci (97%). In contrast, significant genetic differences have
been identified at other loci, enough to justify their separation into
distinct species (39, 40). This is yet to be established for D. fragilis
but may have important clinical and epidemiological implica-
tions. The identification of D. fragilis in individuals without clin-
ical disease raises the question of whether multiple lineages of D.
fragilis exist, some of which may not be associated with disease.
Asymptomatic carriage of pathogenic E. histolytica was known for
many years, and it was not until 1993 that E. dispar was identified
as a separate, nonpathogenic species (40). Since no population-
style studies have yet been conducted on D. fragilis at this time, it
remains to be seen whether D. fragilis exists as a species complex.
Over 6,000 novel nucleotide sequences were made available
with the publication of the D. fragilis trophozoite transcriptome.
These data will facilitate the selection of novel targets for exploring
the genetic diversity of D. fragilis (41). The transcriptome was
sequenced from a cultured isolate of D. fragilis SSU genotype 1,
originally obtained from a patient with GI symptoms from Syd-
ney, Australia (33). The transcriptome is described as sharing
many features present in the genome and transcriptomes of
Trichomonas vaginalis (41–43). More than one-third of D. fragilis
contigs received hits to T. vaginalis proteins with E values of
1.00E49, reflecting the close relationship between these or-
ganisms in spite of their morphological differences. Trophozoites
of D. fragilis were also described as being metabolically similar to
those of T. vaginalis (41). Like T. vaginalis, D. fragilis has also
undergone a massive expansion in its repertoire of BspA-like leu-
cine-rich repeats (44) and actin family genes (43), among several
others (41).
Several transcripts possessing homology to cytotoxic cysteine
proteases of T. vaginalis were identified in the transcriptome and
discussed in reference to the pathogenic potential of D. fragilis (41,
45). As the pathogenic nature of D. fragilis has been debated since
its discovery (26), the identification of potential virulence factors
for future investigation is applicable to this debate. It has been
argued that differences in clinical outcomes reported for D. fragilis
infection may be a reflection of genetic diversity between D. fragi-
lis populations (32). It is suggested that as a first port of call, ex-
amination of genes encoding cysteine proteases and other poten-
tial virulence factors would be of great value, as diversity in these
genes might explain differences in clinical outcomes (26, 32). This
is not unprecedented, as differences in cysteine protease genes
between pathogenic and nonpathogenic Entamoeba spp. have
been noted and have been implicated as one factor among many
that may account for differences in virulence (39). Furthermore,
genetic diversity in cysteine protease genes between isolates of
Tritrichomonas foetus infecting disparate host species (cattle and
cats) has been reported (46). Consequently, the cysteine protease
genes might represent a useful target for the identification of ge-
netic diversity among D. fragilis isolates in future studies.
Before the completion of the D. fragilis transcriptome, only five
protein-encoding gene sequences and 62 nucleotide sequences
were available in public databases, with the vast majority being
derived from the rRNA genes. These rRNA gene sequences have
been studied closely and are the targets for the majority of PCR
and real-time PCR (RT-PCR) tests that are currently available for
D. fragilis (30, 31, 47–51). The availability of the D. fragilis tran-
scriptome means that 6,000 novel sequences are available for
public reference (41). These data will lay the foundations for fu-




D. fragilis possesses a pleomorphic trophozoite stage (Fig. 2),
ranging in size from 4 m to 20 m, with most in the range of 5
m to 15 m (12, 14, 52, 53). Larger forms with sizes upwards of
20 to 40 m are sometimes seen in culture (54). Dientamoeba
trophozoites are typically binucleate, with up to 20% of forms
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being uninucleate (2), although this percentage can vary consid-
erably (53). Nuclear pleomorphism is quite common, with the
nucleus size varying in relation to the rest of the cell (55). In per-
manently stained smears, peripheral chromatin is absent, and the
nuclear membrane is delicate. The karyosome is fragmented and
contains chromatin granules often appearing as chromatin pack-
ets (19). The D. fragilis cytoplasm is often finely granular and often
contains vacuoles and food inclusions along with ingested micro-
organisms (12).
Motility demonstrating characteristic fan-shaped pseudopodia
with irregular lobes and indentations may be seen in freshly passed
specimens or culture media (56, 57) (see File S1 in the supplemen-
tal material). This motility is temperature dependent, and tropho-
zoites become less motile with cooler temperatures (2, 58).
Scanning electron microscopy of D. fragilis trophozoites de-
rived from xenic culture systems showed two main types of cell
populations based on the structure of cell surfaces: ruffled and
smooth cell types (Fig. 3) (7). Ruffled cells accounted for up to
90% of the cell population; however, time interval experiments
showed an increase in the number of smooth cells at 72 h. There
was no statistically significant difference in size between the two
morphological forms. While ruffled cells are observed in other
trichomonads, it is unknown what significance this change in tro-
phozoite surface structure represents (59). While the smooth cell
types observed were initially postulated to represent a pseudocyst-
like stage, experiments to induce pseudocyst formation using ad-
verse environmental growth conditions failed (7). However, as D.
fragilis does not possess undulating membranes or external fla-
gella like other trichomonads, investigation of the formation of
pseudocysts is difficult.
Using scanning electron microscopy on cultured D. fragilis tro-
phozoites, Banik et al. (7) also described for the first time an en-
dogenous D. fragilis virus. This is not unprecedented, as many
protozoa are hosts of their own endogenous viruses, including
Trichomonas vaginalis, which hosts a double-stranded RNA virus
(60). The significance of this is currently unknown, although stud-
ies on T. vaginalis suggest that its presence or absence in T. vagi-
nalis isolates may influence virulence (61).
Precysts
Putative precystic forms of D. fragilis were described recently by
Stark et al. (62). However, a thorough examination of historical
publications regarding this parasite indicates that precystic forms
were described in the literature several times previously. At the
FIG 2 Pleomorphic trophozoites of D. fragilis. (A) Binucleate trophozoite of D. fragilis (stained with a modified iron-hematoxylin stain) (magnification,
	1,000); (B) live D. fragilis trophozoite displaying motility (viewed under phase-contrast microscopy) (magnification, 	400).
FIG 3 Different cell surface structures observed in D. fragilis trophozoites grown in a xenic culture system. (A and C) Smooth (A) and ruffled (C) cell structures
observed by scanning electron microscopy. Ruffled cells accounted for up to 90% of the cell population, although time interval experiments showed an increase
in the number of smooth cells at 72 h. (B) Cells with a slightly textured surface are also observed and may represent an intermediate between the smooth and
ruffled forms.
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time, these reports were dismissed as a misrepresentation of de-
generative individuals (2). The initial description of D. fragilis in
1918 indicated that “extremely minute forms (3.5 m) are not
infrequent” (1). Dobell subsequently described forms that he re-
ferred to as “dwarfs, with diameters of only 3 to 4 m [that were]
also found in cultures. They appear to be formed by rapid division,
without intermediate growth, of normal individuals” (2). In 1923,
precystic forms were described in North America (63), and in
1926, Kudo described precystic forms as “small spherical amoeba
without food particles” that were ~4 m in diameter (64). Wen-
rich conducted a study on the morphological characteristics of
Dientamoeba and described what he believed was a precystic form.
Like other researchers, Wenrich described these precystic forms as
small, ranging from 3.5 to 5 m in diameter, including both uni-
nucleate and binucleate forms with a finely granular and uniform
cytoplasm that exhibits intense staining (65). These forms, de-
scribed many years before, were morphologically identical to
those described by Stark et al. (62) (Fig. 4).
Several researchers dismissed these findings (2, 12), with Dobell
being the most vocal opponent. He stated that it was “inconceiv-
able that D. fragilis would have a cyst stage,” while “Histomonas—
its closest relative also has no cysts” (2). Recently, cyst-like stages
of H. meleagridis have been reported (66, 67). These forms are
similar to those described by Stark et al. (62) for D. fragilis: com-
pletely spherical compact structures with a size of 4 m. These
cyst-like forms were thought to represent the initial stages of true
cyst formation that can withstand harsh environmental condi-
tions (67, 68), although the infectivity of these structures is yet to
be confirmed.
Cysts
Despite recent reports that cyst forms of D. fragilis have never been
reported in humans, it is now understood that this is incorrect
(69). Jepps and Dobell were the first to postulate that D. fragilis
may have a cyst stage that occurred in an animal host and that
humans were an accidental host in which cyst formation did not
occur (1). However, after studying this organism for 20 years,
Dobell concluded that D. fragilis did not produce cysts (2). In
1923, the American protozoologist Charles Kofoid described a
cyst stage of Dientamoeba (63). Then, in 1928, a South American
researcher also described cyst forms in Argentina (70). Then, 20
years later, cyst forms in several patients from Germany were de-
scribed (71). In contrast, many researchers have not reported this
stage in the life cycle of Dientamoeba (72), including Dobell, who
was unable to detect cyst forms from patient samples. He searched
one individual 42 times over a 10-month period. Another case was
monitored for 5 weeks, and stool samples were examined a total of
12 times, to no avail (1).
The successful establishment of a rodent model to study D.
fragilis infection and transmission underpinned the characteriza-
tion of the D. fragilis cyst stage. Following oral inoculation of mice
with cultured trophozoites, the D. fragilis cyst forms were identi-
fied in the feces of infected animals (Fig. 5) (8). It was not until
2014 that D. fragilis cysts from human specimens were reported in
the literature again. This recent study confirmed the detection of
cysts in human clinical samples in two separate laboratories from
different global locations (the United States and Australia) (62).
These cysts are morphologically similar to the cysts reported in
rodents (Fig. 6) (62). Due to the scant number of cysts encoun-
tered in this cohort, only light microscopy was used in this study,
and unfortunately, electron microscopy could not be undertaken
for definitive confirmation of the cyst forms. Further definitive
studies utilizing in situ hybridization are required to allow corre-
lation between the human and animal structures. It should be
noted that D. fragilis cyst forms were incredibly rare in these hu-
man samples. A total of 547 slides were examined, which were
collected over a 2-year period, and only a few cysts were identified
(62). The frequency in which cysts are found in human clinical
samples leads us to believe that they may not be the predominant
transmissible stage in humans and may actually be an aberrant
form in this host.
DIAGNOSTIC TECHNIQUES
Microscopy
One hundred years have passed since the discovery of D. fragilis,
and from that time, there have been few advances in the tech-
niques used to diagnose infections with this parasite. Definitive
diagnosis is based primarily on microscopy utilizing permanent
stains of fixed fecal smears (69). However, newer molecular detec-
tion techniques, such as real-time PCR, are becoming the methods
of choice for clinical diagnostic laboratories, although these tests
are not employed routinely by most diagnostic laboratories.
In wet preparations, D. fragilis appears as a nonspecific rounded
mass, and the characteristic nuclear structure cannot be visualized
in saline or even with the use of iodine preparations (73). The
trophozoite morphology degenerates rapidly, and as such,
prompt fixation of the specimen is necessary (2, 74). Therefore,
detection of D. fragilis using microscopy is solely associated with
the use of a fixation step followed by permanent staining. Many
different stains and fixatives have been used successfully with D.
fragilis. Suitable fixatives include mercury-based compounds (11,
75), sodium acetate-acetic acid-formalin (SAF) (74), phenol alco-
hol-formalin (76), modified Schaudinn’s fixative (77), and thime-
rosal (Merthiolate)-iodine-formalin (78). A wide variety of per-
manent stains have been used to detect D. fragilis, including
Mayer’s hemalum and Lawless’ stain (27), with the most common
stains still in use today being iron-hematoxylin and trichrome
stains (79). In our own experience, SAF used in conjunction with
modified iron-hematoxylin provides the best combination for
staining and fixation, compared to other combinations that we
have trialed over the years. It should be noted that our group has
had little experience with trichrome and fecal fixatives containing
FIG 4 Precystic forms from human clinical stool samples (stained with a
modified iron-hematoxylin stain) (magnification, 	1,000). Precystic forms
are typically smaller (3.5 to 5 m in diameter) and stain more densely than
trophozoites.
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polyvinyl alcohol (PVA), and many laboratories in the United
States use this combination with good effect. The main disadvan-
tages of the use of permanent stains are that they require a highly
trained microscopist to read the stains and are time-consuming
compared to newer technologies.
An alternative to trichrome or hematoxylin staining is the use of
the Chlorazol black stain. Based on our experience, SAF also
works best in combination with this stain. van Gool et al. (80)
described Chlorazol stain used on patient stool samples collected
over three consecutive days. The test was highly effective, rela-
tively easy, and fast to perform, and those authors had no issues in
detecting D. fragilis. A recent study used modified Field’s stain to
differentiate D. fragilis from Blastocystis in patient samples cul-
tured in Loeffler’s medium (81). This modified stain provided
greater contrast between the two organisms and was simpler and
quicker to use than Giemsa and iron-hematoxylin stains. How-
ever, as this stain was only evaluated on cultured parasites, its
performance on clinical stool specimens requires evaluation. Re-
gardless, these results look promising (81).
As with other enteric protozoa, D. fragilis trophozoites are shed
intermittently, and daily shedding is highly variable (31, 80). This
necessitates the examination of multiple stool specimens for op-
timal diagnosis. Hiatt et al. (82) examined the sensitivity of exam-
ining one stool specimen compared to multiple specimens. It was
found that collecting multiple stool samples increased the per-
centage of positive results by 31.1% for D. fragilis. These data
indicate that even in symptomatic patients, the examination of a
single stool specimen could miss a large number of D. fragilis
infections (82). As a result, collection of three specimens on con-
secutive days is recommended for the diagnosis of D. fragilis in-
fection if permanently stained smears are used.
Culture
Parasite culture techniques have been used for nearly 90 years to
detect D. fragilis. A wide variety of culture systems have been used,
including Boeck and Drbohlav’s medium (83), Robinson medium
(84), Dobell and Laidlaw’s medium (85), Cleveland-Collier me-
FIG 5 Transmission electron micrographs of D. fragilis cysts identified in
rodent studies of D. fragilis infection. Dientamoeba cysts are 4 to 6 m in
diameter and possess a distinct cyst wall and a clearly visible peritrophic space.
FIG 6 Binucleate cysts of D. fragilis identified in rodent studies (A and B) and
from human clinical stool samples (C and D) (stained with a modified iron-
hematoxylin stain) (magnification, 	1,000).
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dium (86), Balamuth’s medium (87), and TYGM-9 (88). Dobell
and Svensson were the first to grow “monoprotist” D. fragilis cul-
tures in 1929, as all previous attempts had resulted in overgrowth
with Blastocystis. They used a diphasic medium devised by Dobell,
which was comprised of an inspissated horse serum slant overlaid
with diluted egg whites in Ringer’s solution and supplemented
with rice. He also reported that cultures grew best at 41°C, a tem-
perature much higher than one would expect an intestinal protist
of humans to grow (2).
A comprehensive modern evaluation of several culture media,
including modified Boeck and Drbohlav’s medium, TYGM-9,
modified Loeffler’s slope medium, Robinson’s medium, medium
199, Trichosel, and Tritrichomonas foetus medium, was carried
out at different temperatures and under different atmospheric
conditions for the growth of Dientamoeba (33). It was found that
biphasic Loeffler’s medium in a microaerophilic atmosphere was
the optimal combination for growing D. fragilis. This report also
noted that D. fragilis grew optimally at a temperature of 42°C. To
further optimize the biphasic media reported above, Munasinghe
et al. (89) undertook experiments supplementing the medium
with essential growth nutrients, including cholesterol, iron, and
lipids. Different liquid overlays for this biphasic medium were also
evaluated. When a new liquid overlay comprised of Earle’s bal-
anced salt solution supplemented with cholesterol and ferric am-
monium citrate in conjunction with Loeffler’s slope medium was
used, a 2-fold increase in the number of trophozoites grown was
observed compared to the original Loeffler slope medium de-
scribed by Barratt et al. (33, 89).
Compared to permanent stains, a number of studies have dem-
onstrated that culture techniques are sensitive. Sawangjaroen et al.
(58) found that for the diagnosis of dientamoebiasis, culture was
significantly more sensitive than microscopy. A more recent study
using modified Robinson medium showed a dramatic increase in
the rate of detection of D. fragilis compared to traditional micros-
copy techniques (90). Stark et al. (49) compared PCR and micros-
copy against two xenic culture methods. It was found that the use
of modified Boeck and Drbohlav’s medium was superior to mi-
croscopy, while the use of TGYM-9 medium was less sensitive
than microscopy.
It should be noted that cultivation of luminal parasitic protists
is difficult, time-consuming, and often unsuccessful (91). As such,
these specialized culture techniques are usually restricted to spe-
cialist, research, or reference parasitology laboratories and are not
routinely offered by diagnostic laboratories. Dientamoeba has
been reported to be difficult to establish in long-term culture;
however, short-term cultures are relatively easy to establish before
dying out (91). In our experience, D. fragilis isolates can be con-
tinuously passaged for several years with no major issues. One
major disadvantage of culture systems is that the success of estab-
lishing initial cultures is temperature and time dependent. As
such, stool specimens need to be inoculated promptly (12, 57).
Also, rates of D. fragilis recovery are adversely affected if speci-
mens have been refrigerated, and this greatly reduces the sensitiv-
ity of culture methods (58).
All the culture methods that have been used to grow D. fragilis
are xenic culture systems. These are systems in which the parasite
is grown in the presence of the bacterial flora derived from a pa-
tient’s stool. Attempts to grow D. fragilis in axenic culture systems
have all failed (92, 93), including attempts by our group, which has
so far failed to axenize D. fragilis cultures despite extensive efforts
over several years. The unavailability of an axenic culture system
has contributed to the slow progress of D. fragilis research. Other
parasites such as E. histolytica, Giardia, and T. vaginalis have all
been grown in axenic systems, allowing closer study of the organ-
isms to be undertaken without the interference of the bacteria
associated with xenic systems.
Immunoassays
Immunofluorescence microscopy using commercially available
monoclonal antibodies, several commercial enzyme immunoas-
says (EIAs), and immunochromatographic tests (ICTs) are avail-
able for the detection of antigens for Cryptosporidium, Giardia
intestinalis, and E. histolytica in stool samples (94). However, no
such tests are commercially available for D. fragilis. The develop-
ment of user-friendly tests such as these for D. fragilis might en-
courage the adoption of routine D. fragilis testing by more labo-
ratories.
Chan et al. (92) developed an indirect fluorescent-antibody as-
say to detect D. fragilis in preserved fecal samples. A total of 155
specimens were tested, 42 with no parasites, 9 with D. fragilis, and
104 with various other protozoa. There were no false-positive
readings and no cross-reactivity with the other protozoa, although
two of the nine positive samples gave doubtful results. The authors
of this study concluded that this was due to the low numbers of
trophozoites in the samples. This method showed promise and
indicates that other diagnostic tests such as enzyme immunoas-
says could be developed for this parasite.
PCR
Molecular biology techniques now offer a diagnostic alternative to
traditional methods such as microscopy. Identification of D. fra-
gilis as the causative agent is also important for patient manage-
ment, as specific treatment is often required given the potential for
chronic infections to occur. Available PCR techniques enable
rapid identification of Dientamoeba directly from clinical samples,
with results potentially being available in several hours. These
PCR techniques have been used for the detection of a wide variety
of protozoan parasites from clinical samples (94). Several PCR
assays have now been described for D. fragilis and are listed in
Table 2, with a list of commercially available assays included in
Table 3. It should be noted that these tests are currently not FDA
approved in the United States; however, the Genetic Signatures
assay is currently undergoing the registration process.
Based on the literature, Peek et al. (31) were the first to develop
a conventional PCR assay that amplified the SSU rRNA gene to
detect D. fragilis. While the analytical detection limit of this PCR
assay was 0.1 D. fragilis trophozoites per reaction, the clinical
sensitivity and specificity of the assay were not determined (31).
Another conventional PCR assay and an RT-PCR assay based on
the SSU rRNA gene of D. fragilis were developed soon after (30,
95). To determine the sensitivity of these assays, the SSU rRNA
gene was cloned and amplified. The detection limits were 100
plasmid copies (1 D. fragilis trophozoite) for conventional PCR
and 1 plasmid copy of the SSU rRNA gene (0.01 D. fragilis tro-
phozoites) for the RT-PCR assay (95). When the molecular assays
were compared to microscopy for the detection of D. fragilis, both
PCRs were 100% specific, with conventional PCR having a sensi-
tivity of 88.9% and RT-PCR having a sensitivity of 100% (95).
This RT-PCR assay was later shown to cross-react with T. vagina-
lis, and subsequent studies have shown that it cross-reacts with
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other trichomonads, thus making its use in clinical microbiology
laboratories for the specific detection of D. fragilis questionable at
best (D. Stark, D. Chan, J. Barratt, and J. Ellis, unpublished obser-
vations, 2016).
Given the conserved nature of the SSU rRNA gene among
trichomonads, an alternate RT-PCR assay targeting a 98-bp frag-
ment of the 5.8S rRNA gene was developed (51). This PCR showed
100% specificity for D. fragilis when tested against a range of pro-
tozoa, helminths, bacteria, and yeasts. However, this assay was
tested against only one other trichomonad (T. vaginalis), and fur-
TABLE 2 PCR primers and probes used in conventional, nested, and real-time PCR assays for amplification of D. fragilis DNAd
Assay and gene target Amplicon size Primer or probe Sequence Reference
Conventional PCR
18S rRNA 1.7 kb TRD5a 5=-GATACTTGGTTGATCCTGCCAAGG-3= 30
TRD3a 5=-GATCCAACGGCAGGTTCACCTACC-3=
18S rRNA 850 bp DF400 5=-TATCGGAGGTGGTAATGACC-3= 30
DF1250 5=-CATCTTCCTCCTGCTTAGACG-3=
18S rRNA 364 bp DFpn_1f 5=-GCCAAGGAAGCACACTATGG-3= 155
DFpn_364r 5=-GTAAGTTTCGCGCCTGCT-3=
18S rRNA 662 bp DF1 5=-CTCATAATCTACTTGGAACCAATT-3= 123
DF4 5=-CCCCGATTATTCTCTTTGATATT-3=
ITS1-5.8S 300 bp ssu2 5=-GGAATCCCTTGTAAATGCGT-3= 35
1su1 5=-AGTTCAGCGGGTCTTCCTG-3=
ITS1 300 bp ssu2 5=-GGAATCCCTTGTAAATGCGT-3= 35
5.8s1 5=-TGTGAGGAGCCAAGACATCC-3=
Nested PCR
18S rRNA 662 bp DF1b 5=-CTCATAATCTACTTGGAACCAATT-3= 38
DF4Ib 5=-CCCCGATTATTCTCTTTGATATT-3=
18S rRNA 366 bp DF322Forc 5=-GAGAAGGCGCCTGAGAGATA-3= 38
DF687Revc 5=-TTCATACTGCGCTAAATCATT-3=
18S rRNA 850 bp DF400b 5=-TATCGGAGGTGGTAATGACC-3= 98
DF1250b 5=-CATCTTCCTCCTGCTTAGACG-3=
18S rRNA 403 bp DFF2c 5=-CGGGGATAGATCTATTTCATGGC-3= 98
DFR2c 5=-CCAACGGCCATGCACCACC-3=
ITS1 ~540 bpe Ssu2b 5=-GGAATCCCTTGTAAATGCGT-3= 38
DF-ITSREVb 5=-GCGGGTCTTCCTATATAAACAAGAACC-3=
ITS1 380 bp Df-ITSnesForc 5=-ATACGTCCCTGCCCTTTGTA-3= 38
ITSnesRevc 5=-GCAATGTGCATTCAAAGATCGAAC-3=
Real-time PCR
18S rRNA 78 bp DF3 5=-GTTGAATACGTCCCTGCCCTTT-3= 95
DF4 5=-TGATCCAATGATTTCACCGAGTCA-3=
TaqMan probe 5=-FAM-CACACCGCCCGTCGCTCCTACCG-TAMRA-3=
18S rRNA 101 bp 5DMB 5=-GGCGAAAGCATCTATCAAGTGTAAT-3= 96
3DMB 5=-CGGCATCGTTTAAGGTAGGAAC-3=
TaqMan probe 5=-FAM-ACCCGGGTCTCTGATCCGGTTGG-TAMRA-3=
18S rRNA 662 bp DF1 5=-CTCATAATCTACTTGGAACCAATT-3= 37
DF4 5=-CCCCGATTATTCTCTTTGATATT-3=
5.8S rRNA 98 bp Df-124F 5=-CAACTTGGCTCTTTA-3= 51
Df-221R 5=-TGCATTCAAAGATCGAACTTATCAC-3=
Df-172revT 5=-FAM-CAATTCTAGCCGCTTAT-3=-MGB
a Generic trichomonad primer.
b Outer nested primer.
c Inner nested primer.
d NA, not applicable; FAM, 6-carboxyfluorescein; TAMRA, 6-carboxytetramethylrhodamine.
e The amplicon size for ITS1 is variable.
TABLE 3 Commercially available PCR assays that incorporate a D. fragilis target
Assay Assay type Target Company
EasyScreen enteric parasite detection kit Multiplex PCR using
3-base technology
18S rRNA gene Genetic Signatures
Gastrointestinal parasite Multiplex PCR 18S rRNA gene AusDiagnostics
Rida Gene Dientamoeba fragilis Real-time PCR 18S rRNA gene R-Biopharm
G-DiaFrag Real-time PCR 5.8S rRNA gene Diagenode
LightMixModular Dientamoeba Real-time PCR 5.8S rRNA gene Roche Diagnostics
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ther specificity experiments should be performed. This study also
reported that D. fragilis DNA could be detected in refrigerated
feces for up to 8 weeks. It was also noted that intermittent shed-
ding of D. fragilis had less influence on false negativity rates when
PCR was used for diagnosis than when microscopy was used. This
suggests that while intact parasites may be shed inconsistently in
consecutive stool specimens, parasite DNA is more consistently
detectable during an infection. De Canale et al. (96) also devel-
oped a real-time assay for the detection of D. fragilis and compared
it to a conventional PCR assay. The RT-PCR assay showed 100%
sensitivity and specificity and did not cross-react with clinical
samples containing Chilomastix, T. vaginalis, or Trichomonas
hominis. Like the assay reported by Verweij et al. (51), D. fragilis
DNA was detectable in samples refrigerated for up to 8 weeks.
In addition to RT-PCR, several nested PCR assays have also
been reported in the literature as either a complement to RT-PCR
or a confirmatory assay in clinical surveys of D. fragilis in patients
(97, 98). In a study by Caccio et al. (38) that surveyed for the
presence of D. fragilis in pigs, two assays, targeting either the 18S
rRNA or the more variable ITS1 gene of D. fragilis, were devel-
oped. This study reported issues with the assay amplifying the
ITS1 gene, which cross-reacted with flagellates from different ver-
tebrate classes. However, the assay that amplified the SSU rRNA
gene distinguished between two subpopulations of D. fragilis
based on 8 SNPs observed upon sequencing. This assay was fur-
ther employed in a clinical survey of D. fragilis infections in Brazil
(97). Additionally, a nested PCR targeting the small subunit was
developed in a health care center in Tabriz, Iran, and tested on
patients displaying GI disease (98).
Although D. fragilis is not commonly tested for in all clinical
laboratories, there are now several commercial kits/assays avail-
able for the detection of D. fragilis, either included in a multiplex
format or as an individual RT-PCR (Table 3). The Ridagene kit
was recently used in a prevalence study in Portuguese children
(99). Both the AusDiagnostics and genetic signature assays have
been evaluated, and this work was reported, with both assays
showing good sensitivity and specificity compared to an in-house
PCR (50, 100). It should be noted that while some of these kits
have local Conformité Européenne (CE) marking in Europe and
Therapeutic Goods Administration (TGA) approval in Australia,
no current D. fragilis molecular assay has Food and Drug Admin-
istration (FDA) registration. As such, these assays can be used only
as research tools in the United States and not for routine diagnos-
tics. Currently, commercial kits have an advantage over in-house
protocols in that they do not require extensive and complex opti-
mization or validation. Additionally, these assays can be semiau-
tomated by using liquid-handling robots and automated front-
end extraction systems to allow high throughput (100).
New diagnostic tools are steadily becoming available for the
detection of Dientamoeba, although they are currently in limited
use. Indeed, many laboratories still rely on the same methods that
were available at the turn of the last century. Where many ad-
vances have been made in the detection of other pathogenic par-
asites, D. fragilis has been neglected, and newer diagnostic meth-
ods would be a welcome addition for both laboratories and
physicians. Given the increased sensitivity and specificity of these
molecular assays, where possible, these methods should be used in
clinical laboratories for optimal detection of the parasite. When
PCR is not available, multiple permanently stained smears from
suitably fixed fecal specimens should be utilized.
CLINICAL ASPECTS AND EPIDEMIOLOGY
Since its initial description in the scientific literature (1), D. fragilis
has been reported in all human-inhabited continents. The preva-
lence of D. fragilis varies between 0.4% and 71% depending on the
cohort and the diagnostic method employed (26, 79, 101), gener-
ally with a higher prevalence in developed countries (102), a cor-
relation not usually observed for bowel protozoa. Jepps and Do-
bell (1) initially concluded that D. fragilis was nonpathogenic
based on its “mode of nutrition” and a case of asymptomatic car-
riage that was described in the earliest report on D. fragilis (1).
Soon thereafter, Jepps described 10 cases of D. fragilis infection
from a war hospital in 971 soldiers (2). This led to increased in-
terest and subsequent reporting of the parasite throughout the
world (75). A list of major studies reporting the locations and
prevalences of cases of dientamoebiasis is provided in Table 4. The
clinical presentation of infection ranges from asymptomatic car-
riage to various GI symptoms, including altered bowel motions,
abdominal pain, and diarrhea, often in association with eosino-
philia, which is reported in up to 50% of patients (47, 103, 104).
Immediately following its first description (1), the pathogenic-
ity of D. fragilis was placed under scrutiny. Haughwout and Hor-
rilleno (10) reported D. fragilis in three Filipino children suffering
from GI complaints. Soon afterwards, Gittings and Waltz (105)
described case reports of two children with GI complaints infected
with D. fragilis, who improved clinically following treatment.
Since then, hundreds of studies and case reports have provided
support for D. fragilis as a potential pathogen (26, 27, 106). Based
on an overwhelming majority of reports, patients harboring D.
fragilis commonly suffer from diarrhea and abdominal pain,
which can be of an acute or chronic nature. Some case studies have
also shown that Dientamoeba may be implicated in cases of colitis,
but the association is weak (26, 27, 79). Another weak association
between D. fragilis and IBS has also been described (107); how-
ever, a statistically significant association has not been reported,
and as such, the organism most likely plays no role in this syn-
drome (108).
Wenrich et al. (55) reported the detection of D. fragilis in 4.3%
of stool specimens from 1,060 university students in the United
States. Diarrhea and abdominal pain were the major symptoms
recorded. Hakansson (56) described his own personal experience
with D. fragilis, having obtained a D. fragilis infection himself. He
described the presence of recurrent GI symptoms for 2 weeks;
following treatment with carbarsone, he reported complete reso-
lution of symptoms and eradication of D. fragilis based on post-
treatment stool examinations. Hakansson later described a group
of patients (n 
 12) infected with D. fragilis, half of whom were
suffering from GI complaints (57). These infected patients were
treated with carbarsone, resulting in the clearance of D. fragilis and
improved clinical outcomes (57). Sapero and Johnson (109) de-
scribed the detection of D. fragilis in a group of U.S. Navy person-
nel who were returning from military service in Asia. Dientamoeba
was found in 26% of their stool specimens. Of this group, 27% had
GI complaints (109). Hood (110) also demonstrated that elimina-
tion of D. fragilis from a patient’s stool using arsenicals or oxy-
quinoline compounds usually cured patients of GI symptoms.
Like Hakansson (56), Wenrich (12) described his personal ex-
periences with D. fragilis after infecting himself with the organism
on two separate occasions. Both of these infections were chronic
(2 months and 2 years) and spontaneously resolved with no treat-
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patients Technique(s) Country or region
52 36.25 Fecal specimens from inmates in a mental asylum 80 LM Holland
112 2.4 Fecal specimens from patients examined in a parasitology
laboratory
14,203 LM USA
141 20.1 Fecal specimens from GI outpatients 1,114 LM Israel
201 ND Fecal specimens from patients with Ascaris lumbricoides NA LM Thailand
74 4.2 Fecal specimens submitted for parasitological examination 43,029 LM Canada
202 9.6 Fecal specimens containing Entamoeba histolytica/E. dispar 125 Cultivation Mexico City, Mexico
203 1.1 Fecal specimens from schoolchildren 94 Cultivation Durban, South Africa
138 52 Fecal specimens from adult members of a semicommunal group 81 LM Los Angeles, CA, USA
138 21.1 Fecal specimens from children attending dental and general
pediatric clinics
104 LM Los Angeles, CA, USA
204 8.6 Fecal specimens from children in day care centers 900 LM Toronto, Canada
4 Fecal specimens from adult staff at day care centers 146 LM Toronto, Canada
132 1.3 Fecal specimens from homosexual men 150 LM San Francisco, CA, USA
78 16.8 Fecal specimens examined during an outbreak of GI complaints
in a residential community
125 LM French’s Forest, Sydney, Australia
133 1.1 Fecal specimens from homosexual men with diarrhea 274 LM Chicago, IL, USA
205 21 Fecal specimens from indigenous people 242 LM Irian Jaya, Indonesia
125 3 Fecal specimens from patients with GI disorders 1,350 LM Christchurch, New Zealand
117 82.9 Fecal specimens from children infected with any GI protozoa 123 LM Germany
206 3 Fecal specimens from children in rural communities 266 LM Honduras
207 2 Fecal specimens from subjects with light to moderate
dehydration and diarrhea
100 LM Dominican Republic
58 1.5 Fecal specimens from patients with diarrhea 260 Cultivation Brisbane, Australia
134 25.6 Fecal specimens from HIV-infected patients without diarrhea 82 LM Buenos Aires, Argentina
208 2.3 Fecal specimens from pediatric refugees 87 LM USA
135 91 Sera from healthy children 189 IFA Canada
209 8 People with GI complaints in the Netherlands NA NA Netherlands
210 2.1 Fecal specimens from HIV-negative patients 48 LM San Pedro Sula, Honduras
119 5.1 Fecal specimens submitted for routine microbiological analysis 857 LM Oman
211 5.5 Fecal specimens submitted to a university hospital in Tunisia 27,053 LM Sfax, Tunisia
212 3 Fecal specimens from HIV-positive patients 34 LM North Brazil
213 11.3 Fecal specimens from patients with various GI complaints 151 LM Italy
121 8.8 Fecal specimens from patients admitted to a Turkish
university hospital
400 LM Celal Bayar University, Turkey
127 0.9 Fecal specimens from patients with diarrhea 6,750 LM Sydney, Australia
214 0.82 Fecal specimens from sanitary workers 241 LM Malatya, Turkey
123 6.3 Fecal specimens from patients expected to harbor a parasitic
bowel infection
448 LM and TFT Brussels, Belgium
161 3.7 Fecal specimens from patients with various GI complaints 3,139 LM Italy
215 3.4 Fecal specimens from patients with various GI complaints 1,141 LM Italy
216 4.1 Fecal specimens from patients with various GI complaints 1,989 LM Italy
217 2 Fecal specimens from children and neonates at
Ibn-Sina hospital
350 LM Ibn-Sina hospital, Surt, Libya
218 2.7 Fecal specimens from people in an aboriginal community 112 LM Salta, Argentina
219 2.7 Fecal specimens submitted to a Turkish university hospital 770 LM Turkey
220 8.9 Fecal specimens from patients presumed to be infected with
intestinal parasites
168 LM Egypt
220 29.8 Fecal specimens from patients presumed to be infected with
intestinal parasites
168 Cultivation Egypt
221 0.8 Fecal specimens from HIV-negative MSM 628 LM Sydney, Australia
0.3 Fecal specimens from HIV-infected MSM 618 LM Sydney, Australia
1.1 Fecal specimens from non-MSM patients 622 LM Sydney, Australia
151 11.7 Fecal specimens from patients suspected of harboring
intestinal parasites
103 LM Denmark
48 32 Fecal specimens from patients with GI complaints 397 Combination LM and qPCR Zwolle, The Netherlands
222 0.2 Fecal specimens from schoolchildren 2,975 LM Van province, Turkey
223 14.6 Fecal specimens from people attending complementary health
practices between 2002 and 2004
3,719 LM British Isles
16.9 Fecal specimens from people attending complementary health
practices between 2005 and 2007
2,491 LM British Isles
106 5.2 Fecal specimens from patients with GI complaints 750 qPCR Sydney, Australia
50 5.5 Fecal specimens submitted to the Department of Microbiology
at St. Vincent’s Hospital, Sydney
472 Tandem multiplex PCR Sydney, Australia
(Continued on following page)
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ment. Wenrich (12) described himself as having regular bouts of
diarrhea as a result of both infections, which gradually abated over
time. Soon thereafter, Knoll and Howell (111) reported a study of
six patients with D. fragilis (three children and three adults) who
had acute and chronic GI symptoms for up to 1.5 years. Treatment
of these patients with carbarsone led to the eradication of the
parasite and clinical improvement. Based on these observations,
Knoll and Howell (111) proposed that D. fragilis was pathogenic.
More than 2 decades later, Kean and Malloch (112) reported an
examination of 20,917 stool specimens submitted to the Cornell
University Medical College, New York, NY, over a period of 6
years. Dientamoeba was detected in 2.4% of these cases, and 100 of
these cases were described as “pure” infections, where D. fragilis
was the only potentially pathogenic organism identified. Abdom-
inal pain, diarrhea, and nausea were the most common clinical
signs experienced by these 100 patients, who were mostly U.S.
citizens who had not traveled outside the country. Kean and Mal-
loch (112) found that D. fragilis disappeared from patient stool
specimens following treatment with antiprotozoals and that this
resulted in the resolution of clinical symptoms. In a similarly large
study (74), D. fragilis was found in 4.2% of 43,029 patients from
1970 to 1974 in Ontario, Canada. Higher rates of infection were
found in females than in males, with nearly half occurring in pa-
tients 20 years old. The most common symptoms included di-
arrhea, abdominal pain, and loose stools (74).
In the Parasitology Division of the Clinical Laboratories at the
University of California, Los Angeles, stool samples from 695 chil-
dren were examined for ova and parasites between 1976 and 1978
(113). Dientamoeba was recovered from 65 children (9.4%). A
retrospective analysis involving 35 children was then undertaken.
It was shown that 91% of them had GI complaints, including
abdominal pain, diarrhea, and anorexia. The bowel movements of
these children varied from frequent or daily to episodes of inter-
mittent diarrhea. Increased peripheral eosinophil counts were
also noted for 50% of children with D. fragilis. Following treat-
ment, clinical signs were reduced in severity or were completely
absent upon follow-up, leading those investigators to the conclu-






patients Technique(s) Country or region
224 1.6 Fecal specimens from patients with digestive disorders 8,313 LM Catalonia, Spain
156 21.4 Fecal specimens from patients with clinical suspicion of
intestinal parasitosis
491 qPCR Parma, Italy
225 3.5 Fecal specimens from patients with IBS-associated diarrhea 171 LM Karachi, Pakistan
4 Fecal specimens from patients with IBS-associated diarrhea 171 Cultivation Karachi, Pakistan
4 Fecal specimens from patients with IBS-associated diarrhea 171 PCR Karachi, Pakistan
226 0.04 Fecal specimens from patients experiencing GI discomfort 2,604 LM (wet mount and TS) Rocky Mountain region, USA
227 0.9 Stool specimens from locals and immigrants submitted for
microbiological examination
1,503 GS smears Reggio Emilia, Italy
228 NA Stool specimens from children (aged 15 yr or younger)
containing D. fragilis
41 PCR and IH-stained smears Sydney, Australia




230 23 Stool specimens from children aged 4–16 yr referred to a
secondary medical center
220 Standard laboratory testing Netherlands
224 1.6 Stool specimens from outpatients with digestive abnormalities 8,313 Modified ZN technique Catalonia, Spain






232 15.5 Stool samples of food handlers 8,502a LM Tunisia
233 5 Stool samples from internationally adopted children 1,042 Wheatley’s modified TS
smears
USA
234 1.3 Stool samples from children with diarrhea 225 Modified Ehrlich ZN
method
Turkey
235 1.2 Stool specimens from patients with HIV/AIDS 82 Simplified IH technique Brazil
236 2.2 Stool specimens from patients with IBS 45 PCR Mexico
236 26.7 Stool specimens from healthy controls 45 PCR Mexico
237 8.8 Stool samples from patients with GI complaints, patients
attending Al-Nuseirate Refugee Camp Clinic
319 IH-stained fecal smears Gaza Strip
238 9 Stool specimens submitted to Hacettepe University Faculty of
Medicine Parasitology Laboratory
85,707 Examination of stained fecal
smears
Turkey
239 62 Stool specimens from pediatric patients presenting with
GI symptoms
163 Multiplex qPCR Netherlands
240 0 Stool specimens from patients with IBS 55 TS and culture Turkey
240 0 Stool specimens from patients with gastroenteritis 80 TS and culture Turkey
240 0 Stools from healthy volunteers 50 TS and culture Turkey
101 43 Stool specimens submitted to Statens Serum Institut
in Denmark
22,000a qPCR Denmark
98 2.3 Stool specimens collected from various laboratories 1,000 Nested PCR Tabriz, northwest Iran
a Refers to the number of stool specimens and not individual patients.
b IFA, indirect immunofluorescence assay; ND, not disclosed; NA, not applicable; TFT, triple-feces test protocol; LM, light microscopy; qPCR, quantitative real-time PCR; IH, iron-
hematoxylin; TS, trichrome stain; GS, Giemsa stain; NL, native Lugol; ZN, Ziehl-Neelsen; MSM, men who have sex with men.
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wards, Spencer et al. (114) carried out a retrospective analysis
involving 50 patients with pure D. fragilis infections. Symptoms
including abdominal pain, diarrhea, and nausea were present in
most subjects. Twenty of these patients suffered from chronic
complaints, which had been present from 6 months to 18 years,
with 17 patients having symptoms for over 2 years. Eosinophilia
was found in 53% of patients with chronic symptoms (114). In
another report by Spencer et al. (115), stool samples from 104
pediatric patients were examined, and D. fragilis was found in 21%
of patients. Diarrhea and abdominal pain were the most com-
mon symptoms in patients infected with D. fragilis (115). Two
years later, Turner (116) conducted a study that concluded that
D. fragilis and Giardia lamblia cause very similar spectra of disease
based on clinical data collected from patients infected with either
organism.
In a German study by Preiss et al. (117), in 123 pediatric pa-
tients infected with intestinal protozoa, D. fragilis was found in
102 cases. Acute and recurrent diarrhea were found to be the most
common symptoms in children infected with Dientamoeba, and
one-third of these cases demonstrated peripheral blood eosino-
philia. Antiprotozoal therapy, which led to the eradication of the
parasite, also resolved GI symptoms in these patients. These re-
searchers reported that 21% (21/102) of cases had immuno-
globulin G and/or immunoglobulin M levels that exceeded age-
dependent reference ranges. Five patients also had abnormal
transaminase levels. According to an American study by Gren-
don et al. (118), 237 cases of D. fragilis infection were reported
between 1985 and 1986 at the Washington State Public Health
Laboratory. Nearly 80% of patients reported symptoms associated
with their D. fragilis infection, with clinical manifestations of di-
arrhea or loose stools (118). In a study by Windsor et al. (119), 857
fecal specimens submitted over a 6-month period from Oman
were examined. Dientamoeba fragilis was identified in 4.1% of 857
stool specimens and was the most commonly found enteropatho-
gen. Of those subjects diagnosed with dientamoebiasis, 83% had
abdominal pain, 50% had diarrhea, and some experienced
chronic symptoms lasting up to 2 years (119). A Swedish study of
87 patients retrospectively diagnosed with D. fragilis infection
found the highest incidence in pre-school-aged boys, with most
patients being symptomatic (120).
In a study of 400 patients carried out in Turkey, D. fragilis was
found to be more prevalent (8.8% versus 8.6%) and associated
with more symptoms than G. intestinalis (121). A study carried
out from 2002 to 2003 on 1,989 outpatients attending a day care
center in central Italy found that Dientamoeba was more than
twice as prevalent as Giardia (4.1% compared to 1.8%) (122).
Those patients infected with D. fragilis were more likely to have
clinical symptoms than those infected with Giardia. Vandenberg
et al. (123) found Dientamoeba (6.3%) and Giardia (7.1%) at sim-
ilar prevalences, with the symptoms most frequently encountered
with D. fragilis being abdominal pain and diarrhea (69.2% and
61.5%, respectively). However, patients with D. fragilis infection
were less likely to report nausea and/or vomiting, anorexia, and
weight loss.
A recent study of Portuguese children between 2011 and 2013
found D. fragilis in 8.5% of children hospitalized with acute GI
symptoms. Dientamoeba was associated with diarrhea, fever,
vomiting, and abdominal pain in this patient group (99). Ogren et
al. (124) found an association between D. fragilis and GI symp-
toms in children aged 1 to 10 years from the county of Jönköping,
Sweden.
In Australasia, the prevalence of infection varies dramatically,
ranging from 1.5% in Queensland (58) to 2.2% in New Zealand
(125) and 16.8% in suburban New South Wales (78), while the D.
fragilis prevalence rate in Australian Aboriginal children from ru-
ral areas was 5.0% (126). A more recent prospective study of 6,750
outpatients from Sydney found that D. fragilis was detected in
0.9% of patients when permanently stained smears were used for
diagnosis. Gastrointestinal symptoms were present in most pa-
tients, with over 60% of patients presenting with chronic symp-
toms (127).
In a report by Walker et al. (78), a prevalence of 16.8% was
found in suburban Sydney (78). However, that study included
subjects who were living in an area where many households were
unsewered, and the high incidence of D. fragilis infection was also
correlated with a high incidence of infection by Blastocystis and
other bowel parasites in this group. A similarly high incidence of
D. fragilis carriage was reported in a study from Israel, where
201,750 stool specimens were examined between 1960 and 1969.
A D. fragilis detection rate of 15.2% was reported for these samples
(128).
Dientamoeba fragilis has also been reported in association with
allergic colitis. Cuffari et al. (104) reported a case of eosinophilic
colitis associated with D. fragilis in a female 4-year-old child. The
child presented with a 3-year history of chronic diarrhea. A
colonoscopy was performed, and biopsy specimens were taken.
Areas within the lamina propria showed eosinophilic infiltrates,
and a biopsy specimen from the descending colon showed 50
eosinophils per high-power field. Isolated eosinophils were also
observed infiltrating the glandular and surface epithelia. A diag-
nosis of eosinophilic colitis was made on the basis of histopathol-
ogy, and stool samples for identification of ova, cysts, and para-
sites were collected from the patient. Dientamoeba trophozoites
were detected in the patient’s stool samples. She was treated with
iodoquinol and promptly became asymptomatic and remained so
after follow-up for a number of years (104).
Another case report of colitis associated with D. fragilis was
described, involving a Burmese woman who presented with ulcer-
ative colitis (129). The patient was hospitalized, and sigmoidos-
copy revealed multiple punctate aphthous ulcers with mild to
moderate erythematous, nonfriable, intervening mucosa. Stool
cultures were negative for bacterial enteropathogens. After 1 week
of hospitalization, sigmoidoscopy was ordered, and biopsy speci-
mens were taken. The biopsy specimens revealed shallow ulcer-
ation with evidence of acute and chronic inflammation. When
aspirates from mucosal ulcerations were fixed and stained with
trichrome, many D. fragilis trophozoites were seen. The patient
was treated with diiodohydroxyquin and metronidazole and sub-
sequently made a complete recovery. Based on the clinical, radio-
logical, endoscopic, and histological findings, the authors of this
study concluded that D. fragilis was the cause of this case of inva-
sive colitis (129). Another similar case of ulcerative colitis associ-
ated with D. fragilis in a 9-year-old boy was documented in Can-
ada (130). These case reports suggest that D. fragilis may be
associated with colitis in certain individuals, although the small
number of cases described means that this requires further inves-
tigation. An Australian study by Borody et al. (107) also provides
support for an association between D. fragilis and IBS. However,
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other more exhaustive studies using larger cohorts have shown no
association between D. fragilis carriage and IBS (108).
It has been well documented that higher rates of gut protozoal
infection have been reported among men who have sex with men
(MSM) in developed countries (131, 132). However, this phe-
nomenon is not apparent for D. fragilis. A study of enteric proto-
zoa in MSM over a 2.5-year period found that 48.5% of patients
harbored one or more intestinal protozoa. D. fragilis, however,
made up only 1% of the protozoa found, compared to the E.
histolytica-E. dispar complex, which accounted for 26% (133). An-
other study from the San Francisco Bay area in the United States
reported a prevalence of potentially pathogenic enteric protozoa
of 47% among male homosexual patients. E. histolytica-E. dispar
complex isolates were found in 36% of patients, and D. fragilis was
found in only 1.3% of patients (132). The rates of D. fragilis car-
riage reported in these studies are comparable to those reported
for heterosexual groups. One study in Argentina suggested that
the incidence of D. fragilis infections may be higher in immuno-
compromised patients (134). In all other studies conducted, im-
munosuppression does not seem to be a contributing factor for
infection with D. fragilis, although there have been few reports on
this topic (26).
There has been only one study on the seroprevalence of D.
fragilis. Chan et al. (135) used an indirect immunofluorescence
assay and found that of 189 randomized serum samples from chil-
dren and young adults aged between 6 months and 19 years from
Canada, 91% were seropositive for D. fragilis antibodies. This
study suggests that D. fragilis infection is common in Canada;
however, those researchers did not raise the issue of cross-reactiv-
ity, and the 91% positivity rate could be due in part to this phe-
nomenon.
Not surprisingly, higher rates of D. fragilis infection are often
seen where sanitation and hygiene levels are poor. This is seen in
studies performed on disadvantaged groups and communities
(136, 137). For example, the pioneering investigator S. L. Brug
reported a remarkably high incidence of D. fragilis carriage
(36.25%) in Holland among inmates in a mental asylum (52).
Similarly, high prevalences were reported in the United States in
300 members of a semicommunal religious group. Dientamoeba
fragilis was detected in this community at an incidence of 53%.
Over 81% of D. fragilis-infected patients had GI complaints, most
commonly recurrent or chronic diarrhea, and substandard hy-
giene practices were evident among this group. In accordance with
cultural beliefs, toilet paper was not used after defecation; bare
hands were used to wash the anal area with soapy water. Hand
washing before meals was not a common practice, and meals were
often eaten without the aid of cutlery (138).
There is an overwhelming body of evidence, dating back sev-
eral decades, indicating that treatments that eliminate D. fragilis
result in significant clinical improvement of patients experiencing
GI symptoms (11, 12, 26, 53, 55–57, 74, 103, 104, 111, 112, 114,
117, 125, 129, 139–143). This suggests that D. fragilis plays some
role in the development of GI disease. However, some reports
from northern Europe support a very different trend. In a recent
publication from Denmark (101), a very high incidence of D. fra-
gilis infection (43%) was reported after performing a quantitative
PCR (qPCR) survey involving a large number of stool samples
(n 
 22,484) submitted by subjects for investigation of intestinal
parasitosis. In this same report (101), the authors refer to the
unpublished work of a colleague (L. R. Krogsgaard et al., unpub-
lished data) who observed a similarly high incidence of D. fragilis
infection among healthy Danish adults. As these authors state,
“this is a staggeringly high proportion, particularly for healthy
individuals.” This is, in fact, comparable to the incidences re-
ported by Brug (52) for inmates in a Dutch mental asylum (inci-
dence of 36.25%) and by Millet et al. (138) for members of a
semicommunal group that partook in substandard hygiene prac-
tices (incidence of 53%). In a study from the Netherlands (Hol-
land) by de Wit et al. (144), D. fragilis was detected more fre-
quently in the stool specimens of healthy controls (14.6%) than in
the stool specimens of subjects suffering from GI complaints
(10.3%). A recent large case-controlled comparison study com-
prising 1,515 symptomatic patients and 1,195 healthy controls
detected D. fragilis in 390 symptomatic patients at a prevalence of
25.7% and in 446 individuals in the control group at a prevalence
of 37.3% (145). This study found that D. fragilis was more com-
monly found in healthy nonsymptomatic groups than in symp-
tomatic patients. Another study by de Jong et al. (146) found
higher rates of D. fragilis detection in healthy controls than in
pediatric patients presenting with chronic abdominal pain. Dien-
tamoeba was found at astonishingly high prevalences of 50.6% in
controls and 43.2% in the study group. These authors found no
differences in symptoms of children with and those without D.
fragilis infection, and no relationship between clinical and micro-
biological responses after treatment was found. This retrospective
study suggested no association between chronic abdominal pain
and D. fragilis infection. Another Danish study found high rates of
D. fragilis carriage of between 35% to 41% in primary care patients
diagnosed with IBS (147). All of these studies reporting a high
prevalence of D. fragilis infection used the same diagnostic
method, a real-time PCR method described previously by Verweij
et al. (51). Subsequently, it seems that further testing and evalua-
tion of this assay are warranted to determine if these extraordi-
narily high rates of infection are a true indication of the prevalence
of D. fragilis in Denmark or are artifacts of the test.
In another recent study from Denmark, Petersen et al. (148)
suggest that people harboring D. fragilis are less likely to suffer
from inflammatory bowel disease (IBD) and relate this to the hy-
giene theory. In that study, healthy control groups had a higher
incidence of D. fragilis than did those with IBD. This is in direct
contrast to previous reports that implicated D. fragilis as a cause of
such complaints and reported resolution of symptoms following
antiprotozoal therapy (104, 129, 130). In another Danish study, D.
fragilis was associated with a low frequency of defecation in pa-
tients with IBS (149), which is in direct contrast to the vast major-
ity of reports that suggest that fecal urgency and diarrhea (two
typical IBS symptoms) are associated with D. fragilis carriage. The
study by Engsbro et al. (149) also employed real-time PCR and
reported a similarly high incidence of D. fragilis compared to that
reported in a previous Danish study (101). In contrast to the re-
ports by Engsbro et al. (149, 150), Borody et al. (107) demon-
strated that antimicrobial therapy that eradicates D. fragilis led to
the resolution of IBS-like symptoms.
These reports from northern Europe (101, 149) of remarkably
high D. fragilis carriage (especially in healthy individuals [Krogs-
gaard et al., unpublished]) are perplexing, especially considering
that the test subjects were residing in wealthy, developed nations
where hygiene and sanitation are excellent (151). These reports
are also in direct contrast to the overwhelming majority of reports
from a large number of research groups that suggest that at the
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very least, individuals carrying D. fragilis are more predisposed to
GI symptoms such as abdominal pain and diarrhea than the gen-
eral population (for peer-reviewed articles that strongly support
this point, see references 26, 27, 79, 102, 106, and 152). Further-
more, there is an overwhelming body of evidence dating back
several decades, from numerous investigators, indicating that
treatments that eliminate D. fragilis result in marked clinical im-
provement (11, 12, 26, 53, 55–57, 74, 103, 104, 106, 111, 112, 114,
117, 125, 129, 139–143).
Several reports implicate the human pinworm, Enterobius ver-
micularis, as a probable vector of D. fragilis transmission (72, 153–
155). This is not an unreasonable hypothesis based on the evi-
dence at hand. However, a D. fragilis incidence of 43% in Danish
patients (and a similar incidence in healthy individuals) implies
that at least 43% of the Danish population would also be infected
with, or has previously been infected with, pinworm. This hypoth-
esis, of course, assumes that the pinworm is the bona fide vector of
D. fragilis and that every pinworm isolate in Denmark is harboring
D. fragilis. Given the consistently high D. fragilis incidence re-
ported in this location in healthy and ill subjects, it would be
interesting (and seems necessary) to explore the incidence of pin-
worm infection across a similarly large group of Danish patients.
It is also quite possible that the sensitivity of the real-time PCR
assay employed for routine screening (101) resulted in more cases
being detected in this study than in other studies. However, real-
time PCR surveys have been carried out in other developed na-
tions, and such high incidences have not been reported elsewhere
(49, 156). It is also possible that this is a localized phenomenon,
potentially attributable to local climate or the possible existence of
a resilient, highly transmissible strain of D. fragilis that is endemic
to the region. Regardless, this unusual localized phenomenon cer-
tainly requires closer examination.
TRANSMISSION
Despite the recent description of a D. fragilis cyst stage, the details
surrounding D. fragilis transmission remain unclear (69). Dienta-
moeba fragilis trophozoites are thought to be fragile and unable to
survive for extended periods outside their host. Initially, the ab-
sence of a cyst stage meant that the transmission strategy em-
ployed by D. fragilis remained elusive for many years (69). Several
theories were proposed to address this problem, the most promi-
nent being that transmission occurred via the ova of a helminth
(69, 72). Recent advances in D. fragilis cultivation (33, 89), animal
studies (8, 38), microscopic and electron microscopic studies (7),
and molecular screening (154, 155) have contributed to our cur-
rent understanding of D. fragilis transmission. However, despite
these advances, the mode of transmission employed by D. fragilis
remains elusive and is still a topic of debate.
Cysts or Pinworm?
The hypothesis that D. fragilis may possess a helminth vector is
plausible, as the closest known relative of D. fragilis, H. meleagri-
dis, has a helminth vector (69). The helminth vector theory is also
supported by the work of Ockert (157–159), who reportedly in-
fected himself with D. fragilis by ingesting ova of the human pin-
worm, Enterobius vermicularis. Yang and Scholten (74) and Gir-
ginkardesler et al. (153) later reported a strong association
between the incidence of E. vermicularis and D. fragilis infection,
providing indirect support for the helminth vector hypothesis.
Menghi and colleagues (160) were the first to investigate the
role of the pinworm in the life cycle of D. fragilis using molecular
techniques. Pinworm ova were purified from stool specimens of
D. fragilis-pinworm-coinfected individuals, and DNA on the ex-
ternal surface of these ova was removed by DNase treatment. Fi-
nally, DNA extracted from these ova was tested with a D. fragilis-
specific PCR assay. These experiments failed to detect D. fragilis
DNA within these ova (160). Similarly, reports by Stark et al. (36,
106) identified no association between the occurrence of pinworm
and D. fragilis infection. However, pinworm infections can spon-
taneously resolve, and D. fragilis infections may be chronic, pro-
viding one explanation as to why carriers of D. fragilis may not
always be infected with pinworm (27).
The role of E. vermicularis ova as the vector of D. fragilis trans-
mission was placed under further scrutiny with the recent descrip-
tion of the D. fragilis cyst stage in experimentally infected rodents
(8) and later in human specimens (62). The rodents were con-
firmed to be parasite free by microscopy and D. fragilis free by PCR
prior to experimental infection with D. fragilis. The structures
identified as D. fragilis cysts were never detected in control mice
from the same supplier. While cultured trophozoites were infec-
tious to mice, the same cultured trophozoites could not induce an
infection in rats. Instead, stool from mice containing cysts was
used to successfully induce infection in rats. While this does not
rule out the possibility that E. vermicularis can transmit D. fragilis
via its ova, this study indicates that E. vermicularis is not required
for the transmission of D. fragilis.
Also pertinent to this debate is the fact that D. fragilis is capable
of infecting pigs, having been detected in a population of farmed
swine (38, 161). Humans are the only known host of E. vermicu-
laris. Consequently, it seems unlikely that pinworms would be
responsible for the maintenance of D. fragilis infection in a swine
population, unless the pigs are coming into regular contact with E.
vermicularis ova excreted by humans who are coinfected with both
parasites. Of course, this does not rule out the possibility that
pinworm ova can transmit D. fragilis, although, as with the rodent
experiments, this suggests that E. vermicularis is not an absolute
requirement for D. fragilis transmission.
The role of E. vermicularis as a vector of D. fragilis transmission
is supported by two recent studies that detected D. fragilis DNA in
DNA extracted from surface-sterilized E. vermicularis ova (154,
155). Hypochlorite was used to ensure that the external surfaces of
these ova were DNA free prior to DNA extraction (154, 155). In
both studies, molecular testing confirmed the presence of D. fra-
gilis DNA within a large proportion of ova from patients infected
with both parasites as well as patients with an unknown D. fragilis
infection status (154, 155). As Roser et al. (155) propose, the pres-
ence of D. fragilis DNA inside these ova does not indicate that
viable D. fragilis is present. It was suggested that animal studies
would be useful to determine whether these ova are capable of
inducing D. fragilis infection (155).
The cyst form of D. fragilis is markedly smaller than the tropho-
zoite stage in iron-hematoxylin-stained smears and also stains
darkly in comparison (62). As discussed above, D. fragilis cysts are
also incredibly rare in human stool specimens compared to tro-
phozoites (62). Given their rarity and small size, it is not unrea-
sonable that D. fragilis cysts were overlooked previously. How-
ever, the rarity of these forms in human clinical specimens
suggests that human-to-human transmission probably does not
rely solely on these cysts, unless an incredibly low infectious dose
of cysts is required to establish a D. fragilis infection. Regardless,
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the identification of D. fragilis cysts has epidemiological implica-
tions, as they may represent a risk to drinking and bathing water.
Waterborne transmission of Giardia occurs due to the long-term
survival of the cysts in bathing and drinking water (162, 163).
Subsequently, experiments to assess the infectivity of purified D.
fragilis cysts following long-term storage in water would be worth-
while.
The exact role of cysts and pinworm in the transmission of D.
fragilis has not been sufficiently explored to allow any solid con-
clusions to be drawn. However, there are a number of new leads to
follow and information that should be considered. First, while
associations between pinworm and D. fragilis have been identi-
fied, these associations should be viewed with caution. Polypara-
sitism is common for enteric parasites (26), particularly in young
children (102), and can represents little more than a shared route
of transmission (i.e., the fecal-oral route). Subsequently, reports
by J. Ogren et al. (154) and D. Roser et al. (155) provide better
support for the role of pinworm ova in D. fragilis transmission but
do not confirm that D. fragilis parasites are viable in these ova. The
animal experiments carried out by Munasinghe and colleagues (8)
indicate that pinworm is not an absolute requirement for the
transmission of D. fragilis. Similarly, the fact that D. fragilis cul-
tures that contained only trophozoites (according to microscopic
examination) were infectious to mice indicates that cysts are also
not an absolute requirement for transmission (8). In order to elu-
cidate the true role of pinworm ova and D. fragilis cysts in the
transmission of this organism, further research is required. Ide-
ally, these structures should be purified and fed to animals to
confirm that they are capable of inducing a D. fragilis infection
(72).
An alternative emerging theme of relevance is that some
trichomonads produce pseudocysts as part of their normal life
cycle (164, 165). Literature on trichomonads such as Tritrichomo-
nas foetus and free-living Monocercomonas species (166–168), all
of which are parabasalids that share an ancestor with D. fragilis
(169), shows that these species produce pseudocysts under unfa-
vorable environmental conditions. Pseudocysts are nonmotile,
multinucleated, typically spherical forms without a true cyst wall.
Pseudocysts of T. foetus are infectious and can be found in in vitro
cultures, especially under conditions of stress, such as by cooling
or changes in pH (167). It is unknown whether pseudocyst forms
are present in the life cycle of D. fragilis, although given that they
are thought to facilitate the survival of trichomonads under stress
conditions, this is worthy of investigation (69). Similarly, it is pos-
sible that precystic forms also play a role in D. fragilis transmission
between humans. These forms are more common in clinical spec-
imens than are cysts (62), and it is therefore plausible that precys-
tic forms of D. fragilis represent an additional mode of transmis-
sion, via the fecal-oral route (Fig. 7).
DIENTAMOEBA CARRIAGE IN ANIMALS
A large number of animal species have been investigated as poten-
tial hosts of D. fragilis (129), although only a small number of
animals have been confirmed as natural hosts. Pioneering inves-
tigators reported the presence of D. fragilis in stools of various
primates, including wild monkeys from the Philippines (170),
FIG 7 Life cycle of D. fragilis showing current hypotheses on transmission. D. fragilis is ingested from the external environment by a host species in one or more
possible forms (1). The preferred transmissible form is yet to be determined. Humans are thought to be the preferred host of D. fragilis, although gorillas, pigs,
and rodents are also considered natural hosts (2). Once ingested, D. fragilis travels to the large intestine, where it multiplies by binary fission (3). D. fragilis
trophozoites (A), precysts (B), and cysts (C) are passed into the environment in the feces (4), where they contaminate food and/or water sources. D. fragilis
parasites are then ingested by a new host, completing the cycle. While D. fragilis trophozoites are infectious to laboratory mice, they are noninfectious to larger
mammals. The infectivity of precysts and purified cysts is yet to be demonstrated. It has been suggested that D. fragilis may be transmitted in the ova of the human
pinworm, Enterobius vermicularis (5). Recent reports have confirmed the presence of D. fragilis DNA within E. vermicularis ova, although it is unknown whether
viable and/or transmissible D. fragilis is present in these ova.
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captive macaques (171), baboons (172), and Ecuadorian howler
monkeys (173). One early investigation reports the finding of D.
fragilis in sheep (174), and a recent Nigerian study describes D.
fragilis from a wild rat (175). Early pioneering studies relied on
microscopic examination of stained fecal smears, which is a robust
diagnostic technique in the hands of a skilled microscopist (49).
However, in some of these studies, the staining technique em-
ployed to detect D. fragilis was not disclosed, and photographs (or
drawings) were not provided.
Recent studies have confirmed the natural occurrence of D.
fragilis in two animal species (pigs and gorillas) by using micros-
copy and PCR (38, 176). A study by Stark et al. (176) described the
first report of gorillas as a natural host of D. fragilis and also ex-
amined stools of various other captive animals and birds, includ-
ing several species of monkey, some domesticated ruminants, and
pigs. Nonetheless, D. fragilis was not detected in these other spe-
cies (176). In support of the findings reported by Stark et al. (176),
Lankester and colleagues (177) also found D. fragilis in the stool of
a naturally infected captive gorilla. Interestingly, Lankester et al.
(177) also described the presence of irritable bowel syndrome-like
symptoms in this gorilla. These symptoms resolved upon treat-
ment with metronidazole, which coincided with the eradication of
D. fragilis.
Crotti et al. (161) were the first to identify D. fragilis in the
stools of farmed pigs using Giemsa-stained fecal smears. The role
of pigs as a natural host of D. fragilis was further substantiated in a
later study by Caccio et al. (38), who used PCR and microscopy to
confirm the presence of D. fragilis in farmed pigs. By capillary
sequencing of PCR products derived from the D. fragilis rRNA
genes, Caccio and colleagues (38) demonstrated that the D. fragilis
rRNA and ITS genotypes infecting swine were also of the SSU
subtype found in humans, suggesting that D. fragilis is a zoonosis.
Early attempts to establish an animal model were unsuccessful.
Dobell was unable to establish a D. fragilis infection in himself or
macaques using cultures given orally or in macaques inoculated
rectally. He also inoculated six chicks rectally with cultures of D.
fragilis. One of the chicks developed a cecal infection, which spon-
taneously cleared after 1 week. Cultures from this infection failed
to infect three other chicks (2). In 1945, Knoll and Howell inocu-
lated D. fragilis cultures orally and rectally into kittens; however,
no infection or symptoms were demonstrated, and no amoebae
were recovered at autopsy (111).
It was not until 2013 that a study by Munasinghe et al. (8)
described the successful establishment of a rodent model of D.
fragilis infection, and 1 year later, wild rats were described as a
natural host of D. fragilis (175). Munasinghe and colleagues (8)
were not the first investigators to attempt experimental infections
in rodents. Wenrich (12) was unsuccessful at infecting laboratory
rats. Kean and Malloch (112) successfully infected laboratory rats
with D. fragilis but described these experiments in only minor
detail. In most cases, experimental infections of animals (and hu-
mans) with cultured D. fragilis trophozoites failed, suggesting that
D. fragilis trophozoites cannot survive under the acidic conditions
of the stomach.
According to Munasinghe et al. (8), cultured trophozoites of
D. fragilis were highly infectious to BALB/c mice but could not be
used to establish infections in Sprague-Dawley rats. The rats be-
came infected only after ingesting cysts present in the stools of
BALB/c mice (8). According to data reported in the literature, no
previous attempts had been made to infect mice with D. fragilis
trophozoites. It is difficult to speculate on why BALB/c mice might
be receptive to infection with D. fragilis trophozoites while other
mammals are not. One contributing factor might be the pH of the
rodent stomach (pH 3.0 to 4.0) (178), which is higher than that of
the stomachs of other large mammals (around pH 2.0) and may be
more conducive to trophozoite survival. Furthermore, gastric
transit times are longer in larger animals than in small mammals
(179), which may also be a contributing factor.
PATHOGENICITY
Some 100 years have passed since the discovery of D. fragilis, yet
the debate about its pathogenicity is still ongoing. There is still
little acceptance of the pathogenic potential of D. fragilis despite
the vast evidence that has emerged from clinical studies. While
there is certainly overwhelming circumstantial evidence incrimi-
nating D. fragilis as a pathogen, this is based primarily on case
reports or prospective and retrospective studies describing symp-
tomatic patients whose symptoms were resolved following thera-
peutic intervention and parasite eradication. Other studies have
highlighted higher rates of carriage of D. fragilis in control groups
or cohorts of patients who are asymptomatic (145). These con-
flicting data have led to uncertainty about the role that this para-
site plays in GI disease.
The lack of a suitable animal model hampered the study of the
pathogenicity of this organism for many years. However, the re-
cently developed rodent model is promising and should lead to
further research in this area (8). Three criteria of Koch’s postulates
were fulfilled by using this animal model. All mice inoculated with
D. fragilis became infected, in contrast to the negative controls,
which remained uninfected. In these experiments, infected rodent
groups produced unformed stools and experienced statistically
significant weight loss. Histopathology of infected tissue demon-
strated a mild inflammatory response compared to that of the
control group. Fecal calprotectin levels were also more than two
times higher in the infected group than in uninfected controls.
Additionally, polymorphonuclear white blood cells were micro-
scopically detected in the feces of infected rodents. Finally, cysts
recovered from the feces of infected mice could establish a new
infection in naive mice and rats when administered orally (8).
Infectious doses were as low as 600 trophozoites per mouse. All
of these data would certainly indicate not only the highly infec-
tious nature of the organism but also that D. fragilis is pathogenic
in a rodent animal model. Chronic infections were also docu-
mented in these animal studies, with some infections lasting for 6
months, until the completion of the experiment.
With the recent publication of the D. fragilis transcriptome,
several potential markers of pathogenicity were described, includ-
ing amoebapore-like proteins and putative immunomodulatory
proteins. However, the most abundant virulence factor transcripts
detected were members of the cathepsin L-like cysteine protease
family. Many of the cysteine protease transcripts identified in D.
fragilis closely resembled cytotoxic cysteine proteases previously
identified as virulence factors in T. vaginalis (41, 45). The role of
cysteine proteases in E. histolytica virulence has been clearly dem-
onstrated in overexpression studies (180). Transfection of E. his-
tolytica with vectors that induced the overexpression of certain
cysteine proteases increased their capacity to produce amoebic
liver abscesses in laboratory animals (181). Similarly, E. histolytica
isolates initially incapable of producing liver abscesses in labora-
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tory animals were able to do so when overexpression of certain
cysteine protease genes was induced (181).
Infections with E. histolytica have various clinical outcomes,
and certain isolates are less likely to cause disease than others
(182). Transcriptome studies of virulent and avirulent E. histo-
lytica strains have identified differences in expression levels of cer-
tain genes between isolates, including cysteine proteases, lectins,
and calmodulin (182). Transcripts encoding these proteins were
identified in D. fragilis (41). While the identification of potential
virulence factor transcripts does not confirm pathogenicity, these
sequences provide a lead for future study. Asymptomatic carriage
of D. fragilis has been reported in multiple studies (183), and it
would be valuable to obtain laboratory isolates of these putative
avirulent strains for direct comparison to those associated with
illness. Comparing the transcriptomes of each isolate could deter-
mine whether the expression levels of key virulence proteins differ
between these isolates. Similarly, studies that induce the overex-
pression of proteases and other key virulence proteins in D. fragilis
could shed light on the pathogenic potential of this organism and
identify likely mechanisms of pathogenicity.
PATHOLOGY
Due to limited research on the pathology of D. fragilis infections,
information regarding the pathogenesis and pathology resulting
from D. fragilis infection is minimal. The first pathological find-
ings associated with D. fragilis infection were reported in 1954
from four patients who presented with appendicitis (184). They
reported histopathological changes including lymphoid hyperpla-
sia, organized and acute periappendicitis, catarrhal appendicitis,
fibrosis of the appendix, and numerous D. fragilis trophozoites. It
was postulated by these researchers that “D. fragilis elaborates a
low-grade irritation that induces an inflammatory response” that
causes fibrosis (184). These findings have not been substantiated
by other researchers. The authors of this report also note the pres-
ence of red blood cells in trophozoites of D. fragilis within the
appendix (184). Dobell was actually the first to note the eryth-
rophagocytic nature of D. fragilis (2), a phenomenon also ob-
served in later years in other studies (185). The only other addi-
tional study to look for D. fragilis within the appendix found that
4.8% of 414 appendices examined histopathologically were in-
fected with D. fragilis (n 
 20) trophozoites (186). That study
failed to demonstrate any characteristic histopathology, and no
fibrosis was found in any of the cases (186).
As discussed above, D. fragilis has also been associated with
three cases of colitis. The most recent of these was a case of eosi-
nophilic colitis in a female 4-year-old child who had a history of
chronic diarrhea (104). Another case report described a Burmese
woman who presented with ulcerative colitis (129). The third case
of ulcerative colitis was documented in Canada in a 9-year-old boy
(130). In contrast to these findings, a recent Scandinavian study
found no association between active colitis and D. fragilis in 100
patients with IBD (148).
Kean and Malloch undertook experiments in 1966 to produce
a D. fragilis infection in the cecum of rats. From preliminary stud-
ies, they reported that “edema of the mucosa was evident.” They
also demonstrated that Dientamoeba trophozoites attach to the
cecal mucosa and in doing so damage the underlying cells. How-
ever, no direct invasion of cells or ulceration was evident. Inter-
estingly, no further details were given in that report (112). It was
not until 47 years later that researchers would try replicating the
rodent model of D. fragilis infection (8). Dientamoeba-infected
mice were euthanized and underwent histopathological examina-
tion, which revealed minor pathological changes, including slight
inflammation of the submucosa of the large intestine (Fig. 8).
These inflammatory changes were confirmed by measuring levels
of fecal calprotectin, a marker of inflammatory and neoplastic
disease of the lower GI tract, with average readings taken over 28
days showing levels over twice those of uninfected controls (8).
Infected mice and rats also exhibited statistically significant weight
loss compared to controls. Stool samples from each infected group
were unformed, and white cells were detected via microscopy,
which were absent in the uninfected control groups (8). Chronic
infections were also noted in these mice, with continued shedding
of parasites being noted for 6 months, when the study was con-
cluded. This evidence certainly suggests that D. fragilis is a patho-
gen of rodents, although the long-term effect that chronic D. fra-
gilis infections are likely to have on the gut mucosa is yet to be
determined.
The lack of laboratory animal models has severely hampered
past attempts to study the clinical manifestations of D. fragilis
infection. Various animal species, including macaques, chickens,
and kittens, have all been used as potential animal models of di-
entamoebiasis, with little or no success (2, 111, 112). The recent
establishment of a rodent model of dientamoebiasis represents a
great success for the field and will facilitate future studies on the
pathogenesis of dientamoebiasis.
THERAPY
Numerous studies have demonstrated that antimicrobial treat-
ment that leads to Dientamoeba eradication usually relieves clini-
cal symptoms (187). As such, treatment of symptomatic patients
for whom all other causes of gastrointestinal disease are ruled out
is warranted. Despite the abundance of reports in the scientific
literature highlighting the high incidence of D. fragilis carriage in
humans, very little research has been conducted on the efficacy of
various suitable antimicrobial compounds for the treatment of D.
fragilis infections (Table 5). Several compounds, including carbar-
sone, clioquinol, diphetarsone, doxycycline, erythromycin, iodo-
quinol, metronidazole, tinidazole, ornidazole, oxytetracycline,
paromomycin, secnidazole, and tetracycline, have been reported
as effective treatments for dientamoebiasis (187). It should be
noted, however, that no randomized controlled trials on the effi-
cacy of these compounds using a statistically significant sample
size have been undertaken. Furthermore, most of these reports are
case studies, include only a small number of subjects, and fail to
FIG 8 Intact, healthy submucosa of the large intestine of negative-control
mice (A) compared to mice infected with D. fragilis (B). Infected mice exhibit
mild inflammation and damage to the mucosal layer.
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utilize adequate control groups. To adequately address this issue,
large-scale, randomized, double-blind, controlled trials using all
currently registered antimicrobial agents used in the treatment of
Dientamoeba infections are needed. Until such time as these stud-
ies are undertaken, it is difficult to comment as to what are the
most effective therapeutic agents for the treatment of dientamoe-
biasis. It should also be noted that since infections by other intes-
tinal protozoa (including Blastocystis spp., Giardia, and E. histo-
lytica) are also treated using many of the same drugs as those used
for D. fragilis infection, many reported studies do not clarify which
diagnostic tests were used to identify D. fragilis before and after
therapy. Thus, some of the data may be questionable.
Arsenic-Based Compounds
Early case reports demonstrated that antiamoeba compounds
commonly used in the early 20th century, including emetine-bis-
muth-iodine and the arsenic compound carbarsone, were effec-
tive for the treatment of D. fragilis infections (105). Hakansson
was one of the first parasitologists to advocate the use of antimi-
crobials for the treatment of D. fragilis. He successfully treated
himself and 12 patients with the arsenic compound carbarsone
(56, 57). Knoll and Howell (111) administered carbarsone to three
children and three adults with acute and chronic D. fragilis infec-
tions. In all patients, the clinical symptoms improved quickly after
treatment. Despite its efficacy in eradicating D. fragilis, carbarsone
is no longer available for human use. The newer arsenic com-
pound diphetarsone showed 100% efficacy (188). Despite being a
widely used first-line treatment for intestinal amoebiasis, side ef-
fects associated with the use of arsenicals, such as encephalopathy,
polyneuritis, visual disturbances, and dermatitis, led to the drug
being removed from clinical practice and not licensed for human
use (188).
Tetracycline and Erythromycin
Tetracycline is one antimicrobial currently recommended by the
Centers for Disease Control and Prevention for the treatment of
dientamoebiasis. However, this recommendation is based on only
three case reports. Therefore, the use of tetracycline for treatment
has a very weak basis. Dardick (189) recommended tetracycline
for D. fragilis treatment based on a single case report of a patient
who was successfully treated with this drug. Two other studies,
one comprising a single patient (143) and another that compared
oxytetracycline and doxycycline treatments in 13 patients without
the use of an adequate control group (117), also recommended the
use of these agents. No large-scale studies have examined the effi-
cacy of tetracycline for eradicating D. fragilis, and until such eval-
uations are undertaken, one cannot recommend the use of tetra-
cycline as a treatment option with much confidence. Only one
small-scale study comprising 6 pediatric patients looked at the use
of erythromycin for Dientamoeba treatment. Preiss et al. (103)
reported resolution of clinical symptoms and eradication of the
parasite in 50% (3/6) of patients treated with this compound. As
such, no conclusions can be made regarding the efficacy of eryth-
romycin treatment with data from a single case report. Both
agents have worldwide availability.
Iodoquinol
Iodoquinol is commonly used to treat D. fragilis infections, par-
ticularly in the United States (187). It is commonly used as a lu-
minal amoebicide, but its exact mode of action is unknown. Spen-
cer et al. were the first to report the use of iodoquinol for treatment
of dientamoebiasis (113). Spencer and colleagues concluded that
therapy with iodoquinol or metronidazole was effective based on
a study involving 18 pediatric patients, although the therapeutic
efficacy of the drugs used individually was not confirmed. Millet et
al. (138) treated 12 patients with D. fragilis infection with iodo-
quinol, and elimination of the parasite was achieved in 10 of the 12
patients. Cuffari et al. (104) treated five patients with iodoquinol,
with clinical improvement being shown for four patients. In con-
trast to these reports, Preiss et al. (103) reported treating five chil-
dren with iodoquinol, with only 1/5 responding to treatment. It
should be noted that a low dosage and a short duration of therapy
were used in this study compared to previous studies. Clioquinol,
a compound closely related to iodoquinol, is reportedly an effec-
tive treatment for D. fragilis infection. Bosman et al. (190) re-
ported that this agent was successful in treating 27/33 pediatric
patients with D. fragilis infection. Iodoquinol is readily available
TABLE 5 Treatment studies incorporating study sizes of 10 patients, treatment efficacy, and dosage summaries
Antiparasitic agent Treatment efficacy(ies) (%) (no. of patients) Dosage(s)a Reference
Clioquinol 81.5 (27) 40 mg/kg of body wt/day for 10–21 days 190
83 (12) 250 mg t.i.d. for 7 days 193
Iodoquinol 83.3 (12) 650 mg p.o. t.i.d. for 20 days 138
Paromomycin 98 (61) 500 mg t.i.d. for 7 days 193
80 for parasite clearance and 87 for clinical improvement (15) 25–35 mg/kg daily for 4–5 days 192
Metronidazole 70 (91) 30 mg/kg/day p.o. for 10 days 103
69.6 for parasite eradication and 76.8 for clinical improvement (56) 20 mg/kg for children and 1.5 g for adults daily 194
80 (35) 400–750 mg p.o. every 8 h or daily for 3–10 days 106
66.7 (15) 500–750 mg p.o. t.i.d. for 10 days 123
Secnidazole 97 for parasite eradication and 100 for clinical improvement (35) 30 mg/kg for child stat dose,b 2 g for adult stat dose 121
Ornidazole 92.9 for parasite eradication and 96.4 for clinical improvement (56) 30 mg/kg for child stat dose, 2 g for adult stat dose 194
a t.i.d., three times daily; p.o., orally.
b In medical terminology, a stat dose is a dose that must be administered immediately.
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throughout North and South America; however, it has limited
availability in the United Kingdom, Europe, and Australasia.
Paromomycin
The aminoglycoside paromomycin was first reported as an agent
for the treatment of dientamoebiasis in 1967, with 21/21 cases
responding to treatment (191). A more recent study reported that
four pediatric patients were clinically and parasitologically cured
after treatment with paromomycin (123). A larger study involving
15 pediatric patients with dientamoebiasis who were treated with
paromomycin with follow-up 1 month later noted parasite elim-
ination and complete resolution of symptoms, leading the authors
of this study to state that paromomycin was a viable treatment
option (192). An additional small case series report involving five
symptomatic patients treated with paromomycin showed that
treatment led to parasite clearance and clinical improvement in all
patients (106). The only large study comprised a cohort of 93
patients who were retrospectively analyzed. Paromomycin was
given to 61 patients, and eradication rates of 98% were reported
(193). Paromomycin has worldwide availability.
Metronidazole
Of all the treatment options available for D. fragilis infections,
studies reporting the use of metronidazole are the most discor-
dant. While metronidazole was effective in some studies, several
others describe it as being suboptimal for the treatment of dienta-
moebiasis (187). To complicate the issue further, most studies
reporting on the use of metronidazole are small-scale case reports,
and information on treatment duration and dosage is often in-
complete. This makes the results difficult to interpret. In a study
from New Zealand (125), three patients infected with Dientam-
oeba were treated with metronidazole. Success was achieved in 2/3
patients; however, 1 patient needed a second course of metroni-
dazole in combination with oxytetracycline to achieve parasite
clearance and resolution of symptoms (125). The largest cohort of
patients treated with metronidazole was from Sweden (120), with
32 patients infected with D. fragilis being enrolled in the study. It
was reported that only four patients responded to the treatment
(120); however, no details were given as to the exact dosages or
duration of treatment, so it is difficult to comment on the clinical
effect of metronidazole in these circumstances. Vandenberg et al.
(123) reported that 12/15 patients responded to metronidazole
treatment with both parasitological and clinical cure; however, no
specific information on dosage and duration was provided in this
study.
Preiss et al. (117) were the first to report on the use of metroni-
dazole in a large cohort of 123 pediatric patients infected with D.
fragilis. These investigators reported a treatment efficacy of 70%
with a single dose, while 30% of patients required up to three
additional doses to eliminate D. fragilis and the accompanying
abdominal complaints. These investigators subsequently recom-
mended a 10-day course of metronidazole for D. fragilis infec-
tions. An Australian study showed that metronidazole was effec-
tive in 80% of patients, with 20% showing treatment failure/
relapses (106). Metronidazole is commonly available throughout
the world.
Secnidazole and Ornidazole
Recently, newer 5-nitroimidazole derivatives have become avail-
able. These compounds have the advantage of requiring only a
single oral stat dose and having fewer side effects than metronida-
zole. A Turkish study evaluated the use of secnidazole in 35 pa-
tients with D. fragilis infection (121). Eradication of the parasite
occurred in 34 patients with a stat dose; the remaining patient
required a second dose, whose infection was subsequently re-
solved. This suggests that secnidazole may be effective in treating
dientamoebiasis (121).
Ornidazole, another newer 5-nitroimidazole, was used in a ran-
domized double-blind study comparing the efficacies of metroni-
dazole and ornidazole in 112 patients with D. fragilis infection
(194). Ornidazole outperformed metronidazole by achieving both
clinical cure (96.4%) and parasite eradication (92.9%). Only 6
patients recorded minor side effects in the ornidazole treatment
group, as opposed to 18 in the metronidazole group. However,
sourcing these newer 5-nitroimidazole derivatives may be difficult
in some areas.
In Vitro Susceptibility Testing
The parasitologist W. Balamuth was the first to perform antimi-
crobial studies on D. fragilis in 1953 (195), using six ameobicidal
compounds available at the time: emetine-bismuth-iodine, clio-
quinol, carbarsone, prodigiosin, chlortetracycline (Aureomycin),
and a chemical derivative of carbarsone. The arsenical com-
pounds showed good activity against D. fragilis in a monophasic
medium (195). However, none of these drugs are licensed for
human use today.
Susceptibility testing of D. fragilis ATCC 30948 was performed
with modern drug options, including iodoquinol, paromomycin,
tetracycline, and metronidazole, in a dixenic culture system (93).
The MICs were as follows: 128 g/ml for iodoquinol, 16 g/ml for
paromomycin, 32 g/ml for tetracycline, and 32 g/ml for met-
ronidazole. It is difficult to correlate these MICs to clinical re-
sponses, as this study was undertaken using a dixenic culture sys-
tem containing Klebsiella pneumoniae and Bacteroides vulgatus. It
should be noted that the ATCC strain belongs to SSU ribosomal
DNA (rDNA) genotype 2, while the majority of clinical isolates
belong to the genotype 1 subpopulation (31, 127).
Nagata et al. (196) performed susceptibility testing on four clin-
ical isolates (SSU rDNA genotype 1) of D. fragilis from Sydney,
Australia. Diloxanide furoate, furazolidone, iodoquinol, metroni-
dazole, nitazoxanide, ornidazole, paromomycin, secnidazole,
ronidazole, tetracycline, and tinidazole were tested. The 5-nitro-
imidazole derivatives were the most active compounds against D.
fragilis in vitro, with minimum lethal concentrations as follows: 8
to 16 g/ml for ornidazole and ronidazole, 31 g/ml for metro-
nidazole and tinidazole, 31 to 63 g/ml for secnidazole, 63 g/ml
for nitazoxanide, 250 g/ml for tetracycline, 250 to 500 g/ml for
furazolidone, 500 g/ml for iodoquinol, 500 g/ml for paromo-
mycin, and 500 g/ml for diloxanide furoate. Once again, these
studies were undertaken using xenic culture systems containing
bacterial flora derived from patients’ stool specimens. The absence
of an axenic culture system makes interpretation of in vitro sus-
ceptibility results difficult. The antimicrobial action of these com-
pounds against the bacteria in the cultures could have an indirect
negative impact on D. fragilis growth, as the parasites use these
bacteria as a source of nutrition (196).
Barratt et al. (197) evaluated the in vitro antiprotozoal activities
of various dry plant extracts commonly used as alternate therapies
against parasitic infections. They found that pomegranate peel
extract, garlic extract, goldenseal extract, black walnut extract,
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wormwood extract, wormseed extract, pumpkin seed extract,
grapefruit seed extract, and ginger root extract all had no effect on
D. fragilis.
The activity of several benzimidazoles against D. fragilis was
tested in vitro using four clinical isolates (198). Susceptibility test-
ing showed that albendazole, flubendazole, mebendazole, no-
codazole, triclabendazole, and thiabendazole had no effect against
Dientamoeba. Two beta-tubulin transcripts were sequenced from
a clinical isolate of D. fragilis genotype 1, and the amino acid se-
quences of each beta-tubulin predicted susceptibility to benzimi-
dazoles. This suggests that beta-tubulin sequences cannot be used
as reliable markers for prediction of resistance to benzimidazoles
in trichomonads (198). It should be noted that while Trichomonas
and Giardia are susceptible to benzimidazoles, H. meleagridis is
resistant, although the exact mechanism of resistance remains un-
known (198).
CONCLUSIONS
Numerous clinical and epidemiological studies have confirmed
that D. fragilis is the most prevalent trichomonad parasite that
infects humans. It is therefore inexcusable that so little research
has been undertaken on this peculiar organism. As debate still
surrounds the pathogenic potential of D. fragilis, more research is
needed. Arguably, of all the potentially pathogenic protozoa that
infect humans, the one that we know the least about is Dientam-
oeba. Its life cycle and mode of transmission are poorly defined.
The pathogenesis of dientamoebiasis and its exact mode of action
are unknown. No axenic culture systems are available for this or-
ganism, which impedes future research. The diagnostic tests avail-
able for D. fragilis are limited compared to those for other proto-
zoa, and the tests that are available are in limited use. Molecular
epidemiological studies on D. fragilis are warranted. At least two
distinct 18S rDNA subtypes of D. fragilis exist, and differences in
clinical outcome reported by various investigators suggest that
there is still greater genetic diversity to be found. Further animal
studies would facilitate an improved understanding of not only
the life cycle and transmission of D. fragilis but also the pathogen-
esis of dientamoebiasis. While recent progress has been made on
these aspects, there is still a great deal of work to be done.
Clifford Dobell, one of the parasitologists to first describe D.
fragilis, dedicated most of his working life to the research of this
peculiar organism. He wrote the following statement in reference
to D. fragilis in 1940 (2):
To the protozoologist—if not to the physician—Dientam-
oeba fragilis is now, perhaps, the most interesting of all the
intestinal amoebae of Man: for we know less about it than
about any of the others, and its life-history and activities are
still mysterious.
Ever since I first saw this curious organism, in 1917, I
have been intrigued by its peculiarities, and have taken ev-
ery opportunity of studying it further: yet after more than
20 years’ work and cogitation I am still baffled. . . .
Over 75 years have passed since these words were written, and
remarkably, very little has changed. Our group has been research-
ing this parasite for over 12 years now, and we too remain baffled,
as with every discovery made, more questions arise. Subsequently,
we remain immensely curious about this parasite and hope to
continue our work on Dientamoeba in order to address these ques-
tions, such that our understanding of this organism continues to
improve.
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